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Compounds containing the quinoline and acridine moieties have been utilized extensively in the 
search for new antiprotozoal and multidrug resistance reversal agents. Hence, these moieties 
formed the basis for the synthesis of new compounds. New sulfonamides, ureas and amine 
analogues were synthesized and evaluated for inhibitory activity against trypanothione reductase 
(TryR), in vitro activity against the causative agents of trypanosomiasis, leishmaniasis as well as 
chloroquine-sensitive and resistant malaria. Some were also evaluated as potential tumour 
multidrug resistance reversal agents. 
The best inhibitors oftrypanothione reductase from each class are Naphthalne-2-sulfonic acid [3 
-(6'-chloro-2'-methoxy-acridin-9'-ylamino)-propyl] -amide from the sulfonamides, Naphthalne-
2-sulfomc acid [3-(6'-chloro-2'-methoxy-acridin-9'-ylamino )-propyl]-amide from the ureas and 
N-Benzyl-N'- (6"-chloro-2"-methoxy-acridin-9"-yl)-hexane-l, 6-diamine from the amine series. 
The bisquinoline ureas 1-[2-(7' -Chloro-quinolin-4' -ylamino )-ethy 1] -3-[3-(7" -chloro-quinolin-4"-
ylamino)-propyl]-urea and I, 3 - Bis - [3 - (7' -chloroquinolin -4'-ylamino)-propyl]-urea as well 
as the quinoline-based urea 1-[3-(7' -Chloro-quinolin-4'-y lamino )-propyl] -3 -(2-dimethylamino-
propyl)-urea also showed inhibitory potency against trypanothione reductase. Those compounds 
with noteworthy antiparasitic activity were Naphthalne-2-sulfonic acid [3-(6'-chloro-2'-
methoxy-acridin-9'-ylamino)-propyl]-amide which was active against L. donovani 
(EDso=L9I-LM), the urea I-Benzyl-3- [3-(6'-chloro-2'-methoxy-acridin-9'-ylamino)-propyl]-urea 
active against both L. donovani (EDso=1.9I-LM) and P. falciparum 3D7 (EDso=O.0005I-LM) and 
Kl (EDso=O.OI5I-LM) strains and I-Benzyl-3- [4-(6'-chloro-2'-methoxy-acridin-9'-ylamino)-
butyl] urea which showed activity against L. donovani (EDso=1.9I-LM), T cruzi (EDso=<II-LM) 
and P. falciparum 3D7 (EDso=O.0013/-tM). The bisquinoline urea 1-[2-(7'-Chloro-quinolin-4'-
ylamino)-ethyl]-3-[3-(7"-chloro-quinolin-4"-ylamino)-propyl]-urea and the urea 1-[3-(7'-
Chloro-quinolin -4' -ylamino )-propyl] -3 -(2-dimethylamino-propyl)-urea did not display any 
potency as antitrypanosomal and antileishmamal agents. This did not correlate with the 
inhibitory potency against TryR. The in vivo evaluation of the urea -[3-(7'-Chloro-quinolin-4'-
ylamino)-propyl]-3-(2-dimethylamino-propyl) showed a reduction in parasitemia comparable to 
that of chloroquine. 
Of the compounds tested as multidrug resistance (MDR) reversal agents, Naphthalene-2-
sulfonic acid benzyl- [6-(7'-chloro-quinolin-4'-ylamino)-hexyl]-amide was the most successful. 
Paclitaxel recovered 99% of its activity against a resistant cancer cell line when co-administered 
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INTRODUCTION TO DISEASES 
1.1 INTRODUCTION 
The protozoa that are responsible for parasitic disease in both man and vertebrate 
animals are endoparasitic and live within the tissue of their hosts. They may be located 
in the epithelia or within the cavities surrounded by the epithelial membranes e.g. gut, 
associated with tissue cells or located in tissue fluids. 
Heightened awareness of antiprotozoal resistance to the drugs available as well as the 
poor activity exhibited by available drugs in immunosuppressed hosts has led to the 
renewal of interest in antiprotozoal therapy. For many protozoal infections there is 
adequate therapy available in the form of drugs developed in the 1960s [11. However, the 
value of a large number of these drugs has been lost as a result of the development of 
widespread drug resistance. Furthermore, for most parasitic infections there are few 
alternatives if resistance develops. An additional problem associated in current 
antiparasitic chemotherapy is that drugs available for a number of diseases are 
inadequate because of their variable efficacy and toxicity as well as the requirement for 
long courses of parenteral administration. 
Trypanosoma and Leishmania belong to the kingdom Protozoa, phylum 
Sarcomastigophora, class Zoomastigophora and order Kinetoplastida. They are also 
known as haemoflagellates, referring to the location of the parasite in the host. 
1.2 TRYPANOSOMIASIS 
The genus Trypanosoma is responsible for a number of parasitic diseases that affect 
both man and other vertebrates. Fundamentally, trypanosomes are parasites of the 
bloodstream but some do adapt to intracellular existence. The trypanosome species is 
divivided into 2 major groups namely Salivaria and Stecoraria based on their 
development in the vector and the host. This results in two forms of trypanosomiasis. 
These are African trypanosomiasis, also called African sleeping sickness for which the 
Salivaria group is responsible and South American trypanosomiasis, also called 










1.2.1 African trypanosomiasis: 
a) Introduction 
2 
Human African trypanosomiasis (HAT) is a systematic and central nervous system 
(CNS) infection. It is caused by two geographically distinct species of the group 
Salivaria: Trypanosoma. brucei gambiense (West and Central Africa) and 
Trypanosoma. brucei rhodesiense (East Africa) [21. The infection is transmitted by the 
tsetse fly and the parasites develop in the bloodstream. The two human species can be 
distinguished by the clinical pattern of the disease. Trypanosoma brucei rhodiense 
effects an acute infection with severe toxaemia (a condition caused by absorption of 
toxins formed by microorganisms into the tissues and blood) followed by involvement 
of the CNS resulting in death within a few months. The infection caused by 
Trypanosoma brucei gambiense may go undiagnosed for years with only less severe 
recurring fever spells. The disease may go undetected until involvement of the CNS. At 
this late stage, treatment is more difficult as not many drugs are capable of penetrating 
the CNS. 
b) History of Chemotherapy 
The first trypanocidal drugs were arsenical compounds. Atoxyl 1 (figure 1.1) was the 
first to be tried clinically. It was soon replaced by a less toxic derivative tryparsamide 2 
(figure 1.1). Although tryparsamide was found to be useful in treating the later CNS 
stages of infection, it did have serious toxic side effects on the host. These include optic 
nerve damage, gastrointestinal upsets and severe skin reactions. Convulsions and 
reactive encephalopathy (a disease of the brain associated with toxic poisoning) occur 
less frequently. The main use of tryparsamide was in the treatment of Gambian sleeping 
sickness in the stages of CNS involvement. Resistant strains of the parasite have 
developed due to the long and continued use of the drug. Coupled with this, cross-
resistance to certain related arsenicals has also emerged. As a result, it is rarely used 
today. 
Melarsoprol (Mel B) 3 (figure 1.1) is a trivalent arsenical currently in use. Although it 
seemed to overcome drug resistance, use of this drug has been restricted by severe 
toxicity which can include reactive encephalopathy. It is estimated that up to 10% of the 











Atoxy} (1) Tryparsamide (2) 
Melarsoprol (3) 
Suramin (4) 




Diminazene (6) DFMO (7) 










1.2.2 South American trypanosomiasis: 
a) Introduction 
5 
This form of trypanosomiasis is transmitted by the stecorarian species Trypanosoma 
Cnlzi. The disease affects Central and South America and is widespread in areas where 
conditions favour multiplication of arthropod species of the family Reduviidae, The 
parasite is transmitted via the faeces of these blood-sucking bugs as they deposit 
infective faeces at the site of a bite or mucosal surface. Thus resulting in faecal 
contamination of the mucous membranes or abraded skin. The parasites then invade 
tissue cells of the intestine, oesophagus, peripheral nervous system and cardiac muscle 
cells. In adults, the acute phase of the disease shows only mild symptoms of fever and 
swelling of glands. However, in infants, quite severe reactions can occur, with death 
resulting from encephalitis or myocarditis. The chronic phase, which can last for 
decades leads to progressive disruptions in organs such as the heart, oesophagus and 
lower intestine. Death often follows heart failure due to wastage of this organ. 
b) History of Chemotherapy 
Current treatment is dependant on two drugs, the nitrofuran nifurtimox 8 (figure 1.2) 
and the 2-nitroimidazole benznidazole 9 (figure 1.2). Both have serious toxic side 
effects associated with them, including neuropathy and dermopathy. 
Nifurtimox is effective in clearing T. Cnlzi parasitemia during acute stages of the 
disease. Nitrofurans are the so-called turncoat inhibitors of trypanothione reductase and 
act by inhibiting the reduction of trypanothione disulfide. It has also been used for 
treatment of late-stage disease but the efficacy of treatment for chronic infections is still 
uncertain. The drug exerts its' trypanocidal effect by inhibiting the enzyme 
trypanothione reductase resulting in the production of superoxide and peroxide. An 
intermediate nitro-aryl anion radical (ArN02) may be oxidised to generate superoxide 
anions (02'} These, in turn, can be converted to hydrogen peroxide by the enzyme 
superoxide dismutase (SOD) (equ 1). The hydrogen peroxide will then react with more 
superoxide anion releasing highly toxic ionising OH radicals (equ 2). 
O2 ,. + O2,. + 2H • 2H20 2 (1) 











Tcruzi does not have the ability to release H20 2, as it does not possess the enzyme 
catalase. This leads to the accumulation of H20 2 and hence leads to more of the toxic 
OH radicals. 
Nifurtimox only effects total parasite clearance in 50% of the patients. Toxic side 
effects include gastric upset, anorexia, weight loss, bone marrow depression and a high 
incidence of photosensitive skin rashes. There is also a marked variation in efficacy 
with regard to geographical region, suggesting that differences in parasite strains are 
compounding the problem of drug resistance. 
Benznidazole is used to treat chronic T cruzi infections and is partially effective in 
treating T cruzi acute infection. Toxic effects are common including neuropathy and 
dermopathy in up to 40% of the cases treated. These effects are mainly reversible. As in 
the case with nifurtimox, a marked variation in drug sensitivity of different strains of 
Tcruzi has been observed. 
Nifurtimox (8) Benznidazole (9) 
Figure 1.2. Structures of drugs used in the treatment of Chagas disease. 
1.3 LEISHMANIASIS 
a) Introduction 
Leishmaniasis comprises a group of widely spread diseases and is caused by at least 13 
species and subspecies of the genus Leishmania. These 13 subspecies stem from 4 
major species namely, L. donovani, L. tropica, L. mexicana and L. braziliensis. The 
parasite is transmitted to the mammalian host by the bite of over 50 species of female 
sandflies of the species phlebotomine. Infection in man gives rise to 3 forms of the 











visceral leishmaniasis. The form of the disease depends mainly on the species of the 
causative agent. 
Cutaneous Leishmaniasis is the most common form of the disease complex and the 
lesion is confined to the dermis. This lesion usually appears as a single eruption and 
includes local skin infections, subcutaneous tissue and regional lymph nodes. It may 
heal itself, present as a relapsing ulcer or it may spread to other cutaneous regions via 
the lymphatic vessels. 
The causative agent of mucotaneous leishmania is the subspecies 1. braziliensis 
braziliensis. A single skin lesion will spread to the cartilage and connective tissue of the 
nasopharynx. The result is extensive tissue damage and disfiguration, leading to death 
in severe cases. 
Visceral leishmaniasis (kala-azar) is the result of a systematic infection by the 
subspecies 1. donovani and is considered the fatal form of the disease. It involves the 
reticuloendothelial system (RES) also known as the mononuclear phagocyte system, 
where parasites mUltiply within the macrophages causing fever and disfunction to 
organs such as the liver, spleen, bone marrow and lymph nodes. Relapses' resulting 
from incomplete or unsuccessful treatment of visceral leishmaniasis takes the form of 
post-kala-azar leishmaniasis (PKDL). 
b) History of chemotherapy 
The two antimonic derivatives now in use for the treatment of leishmaniasis are sodium 
stibogluconate (pentostam) 10 (figure 1.3) and meglumine antimonite (Glucantime). 
They remain the drugs of choice for treatment of all forms of leishmania. The main use 
of pentavalent antimonials is in visceral leishmaniasis as other forms of the disease are 
usually unresponsive. Disadvantages associated with these drugs are the lengthy 
treatment required and the fact that subsequent courses of treatment are needed to affect 
a clinical cure in some areas. The drugs have a low toxicity and tolerance is good. 
Exceptions may occur when the dosage is increased as in cases with renal insufficiency 
or when the response by the patient is poor. Hypersensitivity reactions may occur after 











Pentamidine is also effective in the treatment of visceral leishmaniasis, particularly in 
East Africa and the Mediterranean where antimonials are ineffective. Side effects are 
common and toxic including hypoglycaemia and nephrotoxicity. The drug is not used to 
treat any other form of leishmaniasis. 
The antibiotic Amphotericin B 11 is used in the treatment of advanced cases of 
mucotaneous leishmaniasis. Amphotericin B is the most toxic antibiotic in clinical use 
available and reactions to the drug are severe. Upon administration, immediate irritant 
effects, including vomiting, fever; thrombophlebitis (inflammation of the veins) and 
renal damage are observed. Hypersensitivity reactions observed are anaphylaxis, 
generalized pain and convulsions. As a result of these extremely toxic side effects, its 




Amphotericin B (11) 













Malaria is one of the most widespread and dangerous diseases in the world. It is widely 
spread in many Third World countries, including parts of Mrica, Asia, Central America 
and South America. The World Health Organisation estimates that 300-500 million 
cases of clinical malaria occur each year and that this disease fatally affects l.5-2.7 
million people per annum. The disease is currently ranked fifth in terms of the number 
of deaths due to infectious diseases [4l. Human malaria is caused by four Plasmodium 
species: P.falciparum, P. vivax, P. malariae and P. ovale, with P. Jalciparum 
accounting for the majority of infections. The disease has resurfaced as a major public 
health problem over the past three decades primarily due to the development of 
worldwide resistance to many drugs, the most important being resistance by P. 
Jalciparum to chloroquine (CQ) 12 and other drug combinations. 
Malaria is a protozoan infection transmitted by the female mosquito of the genus 
Anopheles during the blood meal. 
12 
Protozoa divide either by binary or multiple fission. Multiple fission involves either a 
single cell, which is known as schizogony, or a zygote, which is known as sporogony. 
Schizogoy is an asexual form of reproduction in which the nucleus divides repeatedly to 
yield a multinucleate cell or a schizont. This then releases small cells with single nuclei 
known as merozoites. Sporogony on the other hand is sexual and involves the release of 
spores or sporozoites from a mature zygote which has been formed from the fusion of 











b) History of Chemotherapy 
The first synthetic drug for the treatment of malaria was qumacrIne 13. CQ later 
replaced quinacrine as the drug of choice for the prevention and treatment of malaria. 
Other antimalarial drugs include proguanil (Paludrine) 14, amodiaquine 15, primaquine 
16, tetracyclines and sulfonamides. The newest agents are mefloquine (Larium) 17, 
halofantrine (Half an) 18, pyrimethamine 19 and artemisinin compounds (20-23) (figure 
1.4). 
Despite the widespread resistance to CQ, the drug is still in use. It is exclusively active 
against the blood stages of the parasite and is used to rapidly cure CQ sensitive malaria 
[51. Prior to the onset of resistance, the drug was well suited for prophylactic and was a 
cheap and effective method of treatment. CQ has been the drug of choice as it is a 
cheap, oral drug with limited host toxicity, good tolerability, good absorption and 
distribution and is effective as treatment and for prophylaxis of this disease. Side effects 
may include gastrointestinal upset, mild headaches and visual disturbances. 
Proguanil 14, also known as chloroguanide, serves as a prodrug that is converted upon 
ingestion to a cyclic triazine metabolite. The use of proguanil is safe and well tolerated 
but has been compromised by the development of proguanil-resistant strains of P. 
jalciparum. Side effects are few and include occasional nausea and diarrhoea. Large 
doses may result in abdominal pain, diarrhoea, hematuria and the transient appearance 
of epithelial cells and casts in the urine. 
Amodiaquine 15 is also active against the blood stages of the parasite but is used much 
less extensively than CQ [61. Significant cross resistance between CQ and amodiaquine 
has been shown. Amodiaquine exerts some serious toxic side effects such as 
agranulocytosis and hepatotoxicity and as a result is not recommended for 
chemoprophylactic use. 
Primaquine 16 is the only drug available for the treatment and clearing of Plasmodia 
from the liver and is thus used in the cure of P. vivax and P. ovale. Toxic effects include 
mild anaemia, cyanosis and haemolysis [6], haemolysis being particularly prevalent in 
glucose-6-phosphate dehydrogenase deficient subjects. Rare symptoms include 
hypertension, arrhymias and symptoms referable to the CNS. 
Mefloquine 17 is a readily tolerated antimalarial drug active against both the sensitive 











resistant falciparum malaria. Mefloquine is generally well tolerated and side effects are 
mild and transient and include nausea, vomiting, abdominal pain and dizziness. 
Symptoms of CNS toxicity present themselves rarely. However, widespread resistance 
has developed in Thailand [71 and Africa [81. 
Pyrimethamine 19 is a 2, 4, -diaminopyrimidine whose main use is in prophylaxis, 
suppression and combined chemotherapy of CQ-resistant strains of falciparum 
malaria[91. The antifolate pyrimethamine-sulphonamide combination and Fansidar 
(pyrimethamine-sulfadoxine) is important in the treatment of CQ-resistant malaria on 
the African continent. Pyrimethamine alone causes no significant toxicity with the 
occasional skin rashes and depression of haematopoiesis. The combination of 
pyrimethamine and sulfadoxine can cause severe cutaneous reactions such as Steven-
Johnson syndrome and toxic epidermal necrolysis. Other reactions include serum-
sickness type reactions, urticaria, exfoliative dermatitis and hepatitis. These adverse 
effects are attributed to the sulfonamide component of the mixture. 
Both quinine 24 and quinidine are active only against the blood stages of the 
parasite[61and are used to rapidly clear parasites form the blood. Artemisinin 20 is a 
sesquiterpene lactone with a peroxide bridge linkage, the peroxide moiety appearing to 
be responsible for the antimalarial activity. The poor solubility of the drug led to the 
synthesis of more soluble derivatives in the form of dihydroartemisinin 21. Its 
esterification and etherification led to artesunate 22 and artemether 23 respectively. All 
of these derivatives have more potent antimalarial activity than artemisinin itself. 
Artemisinin and its derivatives have been proven to be effective against P. Jalciparum 
in sub-Saharan Africa while combinations of artemether or artesunate with mefloquine 
have proved to be effective in the treatment of multidrug resistant malaria in South East 
Asia. On a cautionary note, artemisinin resistance has been developed and demonstrated 
in the laboratory [10]. 
Quinine is more toxic and less effective than CQ as both a suppressive and therapeutic 
agent. Toxic effects resulting from repeated doses of quinine include a cluster of 
symptoms called cinchonism. In its mild form, this includes ringing in the ears, 
headaches, nausea and disturbed vision. Further reactions include hypotension, 
hypoglycaemia, electrocardiographic changes and vertigo [6]. CNS symptoms are noted 











syncope. A decrease in sensitivity of P. falciparum has been reported in some areas 







































Other alternative drugs take the form of atovaquone 25 (figure 1.5) which has broad-
spectrum antiprotozoal activity, pyronaridine 26 (figure 1.5) which is still under 





Atovaquone 25 Pyronaridine (26) 
Figure 1.5. Structures of two alternate antimalarial drugs. 
1.5 MDR CANCER AND ITS REVERSAL BY CBEMOSENSITIZERS 
The incidence, geographic distribution and behaviour of specific types of cancers are 
related to a number of factors which include sex, age, race, genetic predisposition and 
exposure to environmental carcinogens. Cancer is a disease of cells which is 
characterised by a shift in the control mechanisms that govern cell proliferation and 
differentiation. Cells that have undergone this neoplastic transformation proliferate 
excessively and form local tumours that can constrict or invade adjacent structures. 
Ideal cancer drugs would be able to eradicate cancer cells without harming normal 
tissues. However, none of the available agents meet this criteria and one has to weigh 
the benefits against the toxicity in the search for a favourable therapeutic agent. The 
drugs primarily used in cancer treatment are vinca alkaloids (vinbastine, vincristine), 
anthracyclines (doxorubicin), epipodophyllotoxins (etoposide), cisplatin and paclitaxe1. 
Paclitaxel (TaxoI™) 27 is one of the best anticancer agents to be discovered in recent 
years [1 11. In 1992 paclitaxel was approved by the US FDA for the treatment of advanced 
ovarian cancer and in 1994 for breast cancer. Its clinical use has been expanded to the 











of action in promoting tubulin assembly and stabilizing the resulting microtubules[12, 131. 
Unfortunately, like with many anticancer drugs, resistance to paclitaxel has presented 
new challenges. Thus restoring pac1itaxel sensitivity to resistant tumours is of vital 
importance. 
Only a few of the available drugs are effective for each specific tumour type because of 
this acquired or primary drug resistance. Primary resistance involves the absence of 
response on first exposure to the drug while acquired resistance develops in a number of 
drug-sensitive tumour types. This broad-spectrum resistance to anticancer agents is 
what constitutes the multi drug resistance (MDR) phenotype. This form of multidrug 
resistance is associated with an increased expression of an energy-dependent drug 
transport protein, P-glycoprotein (Pgp). This over expression results in less 
accumulation of the anticancer agent as the cancer cell can efficiently pump out the 
hydrophobic molecules [14, ISl. Pgp expels the drug as it enters the plasma membrane. 
Certain drugs have the ability to inhibit this MDR mechanism by binding preferentially 
to Pgp and blocking the efflux channel. This enables the anticancer agent to remain in 
the cancer cell and exert its effect. These inhibitors are called MDR reversal agents 
(chemosensitizers). Ideal chemosensitizers have been described as compounds without 
any intrinsic or inherent cytotoxicity which can reverse the resistance of the cells to the 
cytotoxic action of the drugS[16l. Since the discovery that verapamil, a calcium channel 
blocker, was able to effect the MDR mechanism, many other reversal agents have been 
identified. Included among these are antipsychotic agents (phenothiazine). In the 
presence of appropriate concentrations of chemosensitizers, drug toxicity is greatly 
potentiated in resistant cancer cells and, in many cases; the ICso approaches that of 
susceptible cells [14l. The chemosensitization effect of verapamil is associated with an 
increase in drug accumulation. This process is thought to be the mechanistic basis of 
chemo sensitization. 
The widespread concept presumes inhibition of Pgp activity by competition with the 
cytotoxic agents for the same binding sites [17] It is well recognised that MDR 
chemosensitizers share common features needed for the reversal: they are amphipathic 
drugs and are mostly protonated [15]. These common features are related to the ability of 
the chemosensitizers to interact with the membrane phospholipids [18l. It has been 











amino acid sequences located in the membrane[151. Pearce and co-workers concluded 
that the relative disposition of aromatic rings and basic nitrogen was important for their 
anti-MDR activity [191. Further investigations have estimated several structural features 
of importance for their anti-MDR activity [19] and point to the role of hydrophobicity as 
a space-directed molecular property to explain differences in anti-MDR activity of the 













BACKGROUND AND RATIONALE 
2.1 TRYPANOTHIONE REDUCTASE AS A TARGET FOR 
ANTITRYPANOSOMAL AND ANTILEISHMANIAL AGENTS 
2.1.1 Introduction 
As described earlier, the current drugs available for the chemotherapy of 
trypanosomiasis and leishmanias are inadequate in terms of efficacy, toxic or both. 
Furthermore, resistance to a large number of these drugs has been reported. An 
additional problem is the high cost of the currently available drugs. Hence, there is a 
definite and urgent need for new treatments that are safe, effective and inexpensive. 
Tyrpanothione reductase (TryR) is unique to the parasitic protozoa Trypanosoma and 
Leishmania and is an attractive and validated target for the rational design and 
development of new antiparasitic drugs. Studies have shown that there is a distinct 
metabolic difference between the trypanomastids and their mammalian host. The 
parasites and host utilize differing processes in the control of their intracellular reducing 
environment. Mammals utilize glutathione for this purpose whereas trypanomastids 
utilize the trypanothione system for redox defence [211. TryR is the enzyme crucial to the 
management of oxidative stress in the aforementioned parasitic protozoa. The closest 
related human enzyme is glutathione reductase (hGR). TryR and hGR display mutual 
exclusive specificity for their substrates (trypanothione disulfide for TryR and 
glutathione disulfide for hGR) based on differences in their active sites. Simply put, this 
biochemical difference between host and parasite and the crucial role of TryR for thiol 
homeostasis suggests trypanothione metabolism as a possible target for antiparasitic 
drugs. The effective inhibition of TryR could disable the parasites' ability to cope with 
oxidative stress resulting in death or rendering it more susceptible to the host immune 











2.1.2 The glutathione redox cycle 
Mammalian cells utilise hGR In the management of oxidative stress. When the 
mechanisms that defend the cell against various reactive oxygen species are 
compromised, the cell is said to be under oxidative stress. These reactive oxygen 
species include the superoxide anion (02'-), hydroxyl radicals (RO'), and hydrogen 
peroxide (R202). These reactive oxygen species are cytotoxic due to their ability to . 
modify nucleic acids, thiol-containing proteins and membrane lipids. Reactive oxygen 
species of this nature are produced during normal aerobic respiration. The metabolic 
pathway for detoxification of these reactive oxygen intermediates is the glutathione 
redox cycle (figure 2.1). This is where hGR plays its crucial role. hGR catalyses the 
reduction of glutathione disulfide (GSSG) 28 to glutathione (GSH) 29 in a NADPH-
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Scheme 2.1. Diagram of the reduction of glutathione disulfide 28 to glutathione 29, catalysed by 
glutathione reductase (hGR). 
Glutathione (GSH) participates in the detoxification of organic hydrogen peroxides 
(ROOH). This process involves the use of the enzyme glutathione peroxidase. Two 
GSH molecules are oxidized to the disulfide (GSSG). GSH is regenerated by reduction 
with NADPH. GSH also binds various cytotoxic substances (X in figure 2.1), a process 
mediated by glutathione -S-transferases. 
2.1.3 Trypanothione 
As parasites, trypanomastids are exposed to various reactive oxygen species generated 
by the host redox system. Consequently, an analogous system has evolved In 
trypanosomes and leishmanias. They, however, have no glutathione reductase or 
glutathione redox cycle. They employ trypanothione (Nt, N8 -bis (glutathionyl) 
spermidine) 33 for this task rather than GSH. Trypanothione disulfide Try[Sh 34, 
differs from GSSG only by the presence of a spermidine cross-link (figure 2.2). The 
parasite system is far less efficient than the mammalian redox defence system but has a 
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Figure 2.2. : Structures of Trypanothione disulfide 31and Glutathione disulfide 28. 
19 
Trypanothione 33 is synthesized from glutathione 29 and spermidine 30. Spermidine is 
combined with glutathione by the enzyme glutathionylspermidine (Gsp) synthetase to 
yield monoglutathionylspermidine conjugates 31-32. Trypanothione synthetase (TryS), 
an ATP-dependent enzyme, adds a second glutathione molecule to yield trypanothione 
33. Oxidation yields trypanothione disulfide 34. 
Trypanothione has other functions in the parasite. These include ascorbate homeostasis 
[22], thiol disulfide exchanges, conjugation of metals and drugs [23], synthesis of 
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Figure 2.3. Metabolism oftrypanothione in trypanosomes and leishmanias. 
2.1.4 Structural and binding aspects of the target 
TryR and hGR share close structural and mechanistic similarities. They are both dimeric 
proteins with a monomer molecular mass of 52 KDa. Each subunit is folded into four 
domains, the FAD binding, the NADPH binding, the central and the interface domains. 
There are two identical active sites which are formed by the residues of the FAD, 
NADPH and central domain of one of the monomers and the interface of the other. Both 
have a redox-active disulfide at their active sites. 
Despite a 41% sequence homology between T. Congolese TryR and hGR, the two 
enzymes are mutually exclusive with regard to disulfide substrate specificity as 











explained of the basis of the structure of the active site. The active site of TryR is large 
and negatively charged and contains a hydrophobic pocket for the recognition of the 
spermidine moiety of the substrate. On the other hand, the active site of hGR lacks the 
binding pocket and has an overall positive charge. These factors are responsible for the 
selectivity of inhibitors of either enzyme. 
2.2 INHIBITORS OF TryR 
2.2.1 Introduction: 
Different classes of compounds have been revealed as selective inhibitors of TryR 
These compounds react more weakly with the closest related human enzyme hGR 
Three classes of these selective inhibitors are described below: 
i) Competitive inhibitors. 
They include crystal violet [28], a number of tricyclics based on acridine [291, 
phenothiazines e.g. 35-37 [30], benzoazepine [31], isoalloxazine [32] polyamine derivatives 
e.g. 38 [331, and pyridoquinoline [321 ring structures as well as 2-aminodiphenylsulfides 
e. g. 39-40 [341. None of the aforementioned act as antiparasitic drugs but they could be 
used as leads in the synthesis of more specific inhibitors of TryR 
ii) Turncoat inhibitors (subversive substrates) 
These include nitrofuran and naphthoquinone derivatives. They bind to the NADPH-
reduced enzyme where they transfer electrons to molecular oxygen creating superoxide 
radicals which can trigger lipid peroxidation and other chain reactions. As such, they 
have a strong impact on redox metabolism of trypanosomes. 
iii) Covalent inhibitors 
They include drugs such as carmustine that covalently inhibit TryR but also bind hGR 
[26]. Another example is ajoene [351. 
Results to date suggest that a ligand composed of a moiety that is parasite enzyme 
specific, connected by a tailored spacer to a reactive group capable of covalent 
modification, would show promise as inhibitors of TryR. Peptide inhibitors have been 
tested as potential drug targets. The active site of the enzyme is composed of amino 
acids therefore peptides are conceptually easy to design. Their synthesis is 
straightforward although they do present problems as drugs (metabolism, immune 











selective inhibitors of TryR over hGR [361. Quartemization of a tertiary amine has lead 
to compounds which were found to be strong inhibitors of T.cruzi TryR [361. 
Promazine (35): R=H 
Trifluopromazine (36): R=CF3 
Chlorpromazine (37: R=CI 
2-amino-diphenylsulfide derivatives (38) 
Figure 2.4. Representative structures of selective inhibitors ofTryR 
2.2.2 Tricyclic Inhibitors of Try R 
Imipramine (39): R=H 
Chlomopramine (40): R 
The utilization of rational drug design approaches against TryR [311 has led to the 
discovery of the tricyclic structures mentioned above as specific inhibitors ofTryR over 
hGR. It has been suggested that such tricyclics may bind to TryR with the tricyclic 
group lodged against the hydrophobic wall (formed by Trp 21 and Met 113) (figure 
2.5). An additional hydrophobic cavity, the Z site, lies nearby (figure 2.5) and may be 
accessed by hydrophobically functionalised molecules [371. Phenothiazines and tricyclic 
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Figure 2.5. Schematic summary of the regions in the active site of TryR (not to scale). Adapted from 
Chan et a/ [37J• 
Tricyclics based on the 9, 9-dimethylxanthene moiety such as 41-46 have also been 
investigated as inhibitors of TryR [38J. The study showed that derivatives with a 2-3 
carbon methylene spacer between the tricyclic moiety and the secondary nitrogen shows 
stronger TryR inhibition than those with 1 or no methylene spacer (figure 2.6). 
Nevertheless, these compounds were generally found to be weak inhibitors ofTryR. 
41: R=H,X=O 




43: R=tert-butyl, X=O 











2.2.3 Acridine Inhibitors 
While the crystal structures of TryR [39, 40J and of complexes with its substrates have 
been solved [41, 42J, only one structure of TR with an inhibitor has so far been elucidated: 
the TryR-quinacrine (mepacrine) complex [29]. It shows the atomic interactions between 
TryR and the ligand. Mepacrine (which inhibits TryR [43] but not hGR) is bound in the 
active site close to the hydrophobic wall (formed by Trp 21 and Met 113) with the ring 
nitrogen pairing with Met 113, the chlorine with Trp 21 and the methoxy group with 
Ser109. The positively charged alkylamino chain is directed towards the inner region of 
the active site and may form a water-mediated hydrogen bond with GluI8 (figure 2.5). 
This positively charged group has been shown to playa major role in selective binding 
to TryR [30]. As stated earlier, two binding modes for quinacrine have been predicted [36, 
44]. These were evaluated via molecular modelling using a prediction algorithm used for 
the binding affinity of ligands to TryR. It utilizes the virtual screening of a database of 
2D molecular sketches which it then converts to 3D ligand structures. The first binding 
mode places the tricyclic aromatic moiety in the hydrophobic pocket defined by Trp 21, 
Met 113 and Tyr 110 while the second places it at the Z site, which is approximately 
defined by Phe 396', Pro 398' and Leu 399'(figure 2.5). 
The tricyclic acridine moiety has been investigated as an inhibitor of TryR. Experiments 
with a series of 9-aminoacridines 47-49 (figure 2.7) and acridine revealed that the 9-
aminoacridines were weaker inhibitors of TryR than mepacrine. Kinetic studies showed 
that more than one inhibitor molecule can bind to the enzyme [43]. 9-Thioacridine 50-51 
(figure 2.7) derivatives inhibit TryR with mixed type kinetics [43] but are still less 
efficient than mepacrine. Acridine itself had no demonstrable activity highlighting the 
importance of the alkylamino chain to binding [43]. An increase in one methylene within 


















Figure 2.7. Representative structures of 9amino and 9-thioacridines targeted for investigation against 
TryR 
Members of the class of 9-anilinoacridine topoisomerase II inhibitors bearing electron 
donating 1 '-anilino substituents have been shown to be active against both the 
promastigote and amastigote forms of the parasite Leishmania major [45J and 3, 6-
diNMe2 substitution on the acridine ring increases this toxicity to the leishmania 
parasite [46]. 
2.3 ACRIDINE AND QUINOLINE - BASED DRUGS: 
2.3.1 Application in antiparasite chemotherapy: 
Some of the very first known antimalarial drugs have been based on the acridine and 
quinoline moieties as a substructure. Historically the quinolines are the most important 
group of antimalarials. Quinine 24 was isolated from the bark of the cinchona tree and 
for centuries was the only treatment available. The first synthetic antimalarials yielded 
such drugs as quinacrine. Further work yielded such drugs as amodiaquine, primaquine 
and CQ. Although primaquine and amodiaquine displayed significant toxicity to the 
parasite, CQ became the drug of choice for almost five decades. With the development 
of parasite resistance to CQ, the search to find new antimalarials had begun. Currently 











the treatment of malaria, pyronaridine. A senes 4-aminoquinoline mannich base 
antimalarials have been shown to be active against both CQ-sensitive and CQ-resistant 
strains of P. Jalciparum [471. 
Although quinoline-containing compounds have been used primarily for the treatment 
of malaria, their usefulness has been extended to other parasitic diseases. 8-
Aminoquinoline (8-AQ) compounds have been extensively studied smce the 
antileishmanial properties of primaquine were identified. An 8-
alkoxypiperazinoalkylamino analogue, moxipraquine, showed promlsmg 
antitrypanosomal properties as well as antileishmanial properties against cutaneous 
leishmaniasis [481. CQ has also been investigated in terms of its antileishmanial 
properties and has been shown to have moderate in vitro activity against the amastigote 
cell line in L. mexicana [49J. 
Acridines have immense utility in both the pharmaceutical and dye industries[50]. The 
discovery of acridines as antimalarial and antitumour agents has led to intensive interest 
and synthesis of several drugs based on acridine [50-521. Of particular relevance to 
tropical diseases, quinacrine has been used in the treatment of cutaneous leishmaniasis 
and its in vitro activity against T. cruzi is known [53, 541. As described before, quinacrine 
has also been used in the treatment of malaria. Recent investigations have revealed a 
number of 9-anilinooacridines and bis (9-amino-6-chloro-2-methoxyacridines) as 
having antimalarial, antileishmanial and antitrypanosomal activities [46,55,56]. 
2.3.2 Application to multidrug resistance (MDR) reversal in cancer: 
As described earlier, chemosensitizers block the efflux of the anticancer agent allowing 
it to stay in the cell and exert its effect. Included among these chemosensitizers are 
quinine and chloroquine . The ability of the antimalarial drugs chloroquine and 
primaquine as well as other quinolines to act as MDR reversal agents for vinblastine-
resistant (CEMlVLB 100), and vincristine-resistant (KS62/ADM) cancer cell lines has 
been previously reported [57-59]. 
Experiments were conducted to test the importance of the quinoline moiety. When the 
quinoline ring in 52 was replaced by a naphthyl 53 or phenyl 54 ring, the resulting 











reversing activity of 52 (figure 2.8) was 3-4 times higher than that ofverapamiL Thus, it 
was concluded that the quinoline moiety seemed to play an important role in 




Figure 2.8. Representative structure of the aromatic derivatives investigated by Suzuki et al[591. 
Within the context of paclitaxel chemosensitizing agents, some of the quinidine, quinine 
and quinacrine antimalarial drugs have recently been reported to overcome in vitro and 
in vivo paclitaxel resistance in vinblastine resistant (CEMlVLBlOO), non-Hodgkin's 
lymphoma and hormone-refractory prostate cancer cells [60-621. 
2.4 RATIONALE 
Chloroquine and primaquine are both drugs containing the biologically important 
quinoline moiety. Hence, this moiety has been utilized extensively in the drug discovery 
process towards the discovery of new, effective, potent and safe antiparasitic drugs. 
Since the discovery of the ability of CQ to act as a chemosensitizer in enhancing the 
cytotoxicity of vinca alkaloids e.g. vinblastine [57] in vinblastine resistant cancer cells, 
much research has gone into the investigation of the ability of other quinoline-
containing drugs to effect the same result (58, 591. 
Mepacrine contains the biologically active moiety acridine. Hence, it is known that the 
acridine moiety exhibits promising antiparasitic activity. It has also shown activity as 
MDR reversal agents. As mentioned earlier, studies have shown the importance of this 
moiety in the process of drug discovery. In terms of the inhibition of the enzyme 











hydrophobic pocket and since the elucidation of the mepacrine TryR complex, there is 
much interest in further investigation into the optimum structure for binding to this 
enzyme via structure-activity relationships. 
Consequently, both moieties are attractive targets on which to build scaffolds and 
diversify for the purpose of exemplifying structure activity relationships. 
2.4.1 Acridine derivatives 
We became interested in testing the binding model of quinacrine by incorporating 
methylene spacers between the tricyclic moiety of 13 and a second hydrophobic 
aromatic moiety. This led to the preliminary design of sulfonamides 55-58 ureas 59-62, 
and amines 63-66 (figure 2.9). The amine, sulfonamide and urea moieties were 
incorporated with a view to improving solubility properties of the molecules. 
Substituted ureas have been shown to have important biological activities [63,64] and are 
a common structural motif in biologically active molecules [65, 66]. The urea is 
considered a nonhydrolysable surrogate of an amide bond. We were also interested in 
the in vitro antiparasitic activities of these compounds in view of previous 
aforementioned literature reports on related compounds [46,55,56]. Series 67-69 further 
investigated this model. Work by W. N. Hunter on the X-ray crystal structure of 
mepacrine mustard bound to TryR (unpublished results, personal communication to Dr 
K. Chibale) together with the theory on binding modes, presented us with the 
opportunity to test the importance of the methoxy group in TryR inhibition by 









































Figure 2.9. Structures of acridine compounds targeted for synthesis. 
CI 
2.4.2 Quinoline derivatives 
29 
Since primaquine is the only structural class of compounds that shows activity against 











the 6-methoxy-8-aminoquinoline drugs carrying a terminal tertiary amino group on the 
side chain, with 2 or 3 carbon atoms between the nitro gens on the side chain, display 
undesirable toxic reactions [67, 68]. Coupled with this, hydrophobicity is an important 
feature in MDR reversal agents. Consequently, our research has been aimed at the 
manipulation of this terminal tertiary amino group to form sulfonamides. Target 
compounds synthesized of that nature are 74, 75, and 76 (figure 2.10). 
Following on from the previously described amide-based 5-alkoxyquinolines with 
MDRR activity [59], we targeted some aromatic quinoline sulfonamide derivatives with 
varying methylene spacer lengths as well as bisquinoline ureas and ureas for 
preliminary studies. This is in view of recent observations that CQ derivatives with 
appropriate alkyl chain spacer lengths appear to evade the mechanism(s) responsible for 
resistance to CQ in resistant malarial cells [69-71]. Since hydrophobicity is an important 
feature in MDR reversal agents, we reasoned that the presence of a sulfonamide proton 
should provide us with a diversity point for introducing various hydrophobic groups 
during the exploration of SAR The urea moiety was incorporated with a view to 
improving solubility. Other quinoline compounds which were synthesized in this regard 
are 77-84 (figure 2.10) as well as the amines 85 and 86 (figure 2.11). Bisquinolines 
have been shown to inhibit the growth of CQ-sensitive and CQ-resistant parasites [72]. 
Consequently, several bisquinoline urea compounds 87-88 and a urea derivative 89 
were synthesized via their respective carbamate derivatives, 90 and 91 (figure 2.11). 
Once again the urea moieties were incorporated with a view to improving the solubility 
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3.1 CHEMICAL SYNTHESIS 
3.1.1 Synthesis of sulfonamides 55-58 
The aminoalkylacridine subunits 92-95 were prepared from the treatment of 
commercially available 6, 9-dichloro-2-methoxyacridine 96 with an excess of the 
appropriate diaminoalkane species (Scheme 3. 1){73J• A large excess of the 
diaminoalkane species is required to avoid dimerisation. The four different amines 92-
95 were placed in separate vials and dissolved in a small amount ofDMF. The arnines 
were treated with 1.4 equivalents of 2-naphthalene sulfonylchloride and 2 equivalents of 
triethylamine (scheme 3,1). After 14 hours the reaction was complete. Water was used 
to quench the reaction. 56 and 57 formed solid precipitates upon addition of the water 
and simple filtration yielded the desired products. On the other hand, compounds 55 and 
58 separated out as oils and were extracted with ethyl acetate. The resulting crystals 
were recrystallized to yield the product. 
CI 
Cl 
Cl a N-(CH1)" -NH1 b 
H ------~.~ 
92-95 55-58 
Scheme 3.1. Reagents and conditions: (a) 32 equiv. of diaminoalkane, phenol, 90oe, 4h, 74-95%; (b) 1.4 
equiv. of 2-naphthalene-sulfonyl chloride, 2 equiv. ofEt3N, DMF, 20oe, 14h, 43-94%. 
Although direct amination of an aromatic system at the Sp2 hybridised carbon via 












palladium-catalysed chemistry, in this system amination occurs via nucleophilic 
substitution of the 9-chloro group (Scheme 3.2). This is presumably due to resonance 
stabilization facilitated by the acridine nitrogen. Mesomeric release of electrons on the 
chlorine atom into the ring system results in resonance stabilization with the negative 
charge residing on the acridine nitrogen (Scheme 3.3). Although resonance stabalization 
can also be achieved through the chlorine atom at position 6, the proximity of the 
acridine nitrogen to the chlorine at position 9 is the driving force for nucleophilic attack 
at position 9. This resonance release to the acridine nitrogen creates an electrophilic 

































Scheme 3.3. Resonance stabilization facilitated by the acridine nitrogen. 
Table 1. Table indicating the no. of methylene groups 
from amines and their synthetic yields 
















The classical synthesis of ureas involves the reaction of amines with isocyanates. 
Isocyanates themselves are prepared from amines by reaction with phosgene. This 
presents a problem if the desired isocyanates are not commercially available. A novel 
method of synthesis utilizes alkyl and arylamines and di-tert-butyldicarbonate and 
DMAP [74J The isocyanate is generated from the amine and trapped in situ with excess 
amine. This yields symmetrical and unsymmetrical ureas. An alternative method for 
small library synthesis involves the use ofnitrophenylcarbamates [75]. 
The amines 92-95 were placed in four different vials and dissolved in a small amount of 
dichloromethane. They were then treated with 1.1 equivalents of benzyl isocyante. TLC 












precipitate that had formed during the reaction was isolated by filtration. Only 61 and 
62 required further purification by column chromatography to remove side products that 
could not be removed by washing after filtration. Spectroscopic NMR evidence of the 
benzylic protons (B 4.3-4.4) as well as those of the urea NH (B 4.8-5.0) groups 








Scheme 3. 4. Reagents and conditions: (a) 32 equiv. of diaminoalkane, phenol, 90°C, 4h, 74-95%; (b) 1.1 
equiv. of benzyl isocyanate, CH2Ch, 20°C, 4h, 60-96%. 
3.1.3 Synthesis of amines 63-66 via reductive ami nation of benzaldehyde 
The amines 92-95 were placed into four separate vials and dissolved in a small amount 
of methanol. To these solutions 1.5 equivalents of benzaldehyde was added (Scheme 
3.5). The vials were shaken for 2-3 hours and treated with amberlyst IRA-400 
borohydride resin to reduce the imine formed in situ. The resulting slurry was then 
shaken for an additional 24 hours to effect complete reduction to the secondary amine. 
The resin beads were removed by filtration and washed with several aliquots of 
methanol. Excess benzaldehyde was removed via column chromatography to give the 
products in moderate yield. Alternatively, chromatography could have been avoided and 
excess benzaldehyde trapped using a resin-bound amine which could have been 
removed from the product solution by filtration. The mechanism for this reductive 













a ... b,c NH-(CH,).-NH ~ 
92-95 63-66 
Scheme 3.5: Reagents and conditions: (a) 32 equiv. of diaminoalkane, phenol, 90De, 4h, 74-95%; (b) 
1.5.equiv. of benzaldehyde, MeOH, 20Ge, 2-3 h; (c) 2 equiv. of Amberlite IRA 400 resin, MeOH, 20De, 
24 h, 48-70%. 
The first step involves nucleophilic addition of the amine to the aldehyde carbonyl to 
give a dipolar intermediate. Proton transfer from nitrogen to oxygen then yields a 
nonpolar amino alcohol intermediate. This is followed by dehydration of the amino 
alcohol intermediate to give the neutral imine and water. Reduction of the imine gives 















Scheme 3.6. Mechanism for reductive amination of benzaldehyde. 
The sulfonamides 55-58, ureas 59-62 and ammes 63-66 were shown via 
thermogravimetric (TG) analysis to have water included within the crystal structure of 












dichloromethoxyacridine moiety as well as qumacnne, a number of methods were 
employed before finding success with the use of boron tribromide. Since the signal for 
the protons of the methoxy group resonates in a very distinctive position in the proton 
NMR spectrum, this was used as the primary indication of conversion of the methoxy 




Scheme 3.7. General scheme for demethylation of quinacrine 
a) Iodotrimethylsilane (TMSI) 
The use of organosilicon reagents has gained ground in organic synthesis in recent 
years. The high bond energy of the silicon~oxygen bond makes it thermodynamically 
favourable to use with a reagent that possesses a weak Si~X bond and react it with an 
appropriate oxygen-containing molecule to fonn a silicon-oxygen bonded intermediate, 
which can then be transformed to another product in a subsequent step [76]. One such 
reagent is iodotrimethylsilane (TMSI) [76]. TMSI needs to be freshly prepared under 
strict anhydrous conditions from chlorotrimethylsilane and magnesium iodide, 
phenyltrimethylsilane and iodine or hexamethyldisiloxane/iodine/aluminium powder. 
The reagent needs to be isolated from the reaction mixture by distillation. 
Phenyltrimethylsilane/iodine reagent can be prepared in situ but requires a very high 
reaction temperature and iodine may cause side reactions. The discovery of the simple 
chlorotrimethylsilane (TMSCI) reaction with sodium iodide in acetonitrile has proved to 
be an inexpensive and effective alternative. The TMSI reagent is generated in situ and 











ethers cleave faster (Scheme 3.8). An excess of sodium iodideis crucial to the success of 
the process as it stabalizes the TMSI. If the reaction is allowed to proceed for longer 
periods, the intermediate silyl ethers are converted to alkyl iodides. Simple hydrolysis 
of silyl ether yields the alcoholic products. 
ROR' ,.. 
r 
ROH + R'OH 
Scheme 3.8. Proposed method of action of TMSI. 
Our attempts to use this reagent in the demethylation of both quinacrine 13 and 6, 9 
dichloro-2-methoxyacridine 96 were unsuccessful. 13 or 96 and 3.8 equivalents of 
sodium iodide were dissolved in acetonitrile. To this solution 3 equivalents of TMSCI 
was slowly added. The reaction mixture was stirred at room temperature before being 
brought to reflux. 
A possible explanation may lie in understanding the mechanism (Scheme 3.9). 
Nucleophilic displacement of the iodide by the oxygen is the fIrst step. This iodide then 
reacts to demethylate the resulting species. Base-mediated hydrolysis of the silyl ether 
with water yields the alcohol. A clear byproduct of the reaction is methyl iodide. Since 
TMSI is oxophilic, the acridine nitrogen may be free to react with the methyl iodide 
resulting in alkylation of this nitrogen yielding water-soluble quarternary salt. Addition 
of water upon workup may result in loss of the product. This general mechanism is the 












I I C! -SI-
C! -Sl-C! I ·~I~ I~ 0-CH3 
:PJ 0-CH3 'Si-I ® ~ ... /' .. e OR CI I CI 
+CH1I 
OR 














+ CH3I + (CHlhSiO 
Scheme 3.9. Possible mechanism of TMSI-mediated demethylation. 
b) Diisobutylaluminium Hydride (DmAH) 
The Lewis acid properties of this reagent allow it to form donor-acceptor complexes 
with ethers. The stability of these structures depends on the structure of the Lewis bases 
but this interaction does seem to be weak with aromatic ethers [77]. The reagent has 
proved useful in the demethylation of aromatic steroidal ethers [78]. 
Attempts at demethylation of 6, 9, dichloro-2-methoxy acridine 96 rendered the phenol 
97 in 24% yield but demethylation of quinacrine proved to be unsuccessful. The 
dichloromethoxyacridine was dissolved in toluene and 6.2 eq ofDIBAH was added and 
the solution refluxed for 10 hours. The limiting reagent had been consumed and 



















Scheme 3.10. Reagents and conditions: (a) 6.2equiv DffiAH, toluene, reflux, lOb, 24%. 
c) Pyridine Hydrochloride (pyr.HCl) 
Pyridine hydrochloride has been used quite extensively in the cleavage of ether linkages 
[79.81]. The reagent was used in the absence of solvent as is the normal practice and the 
reaction mixture heated to 210°C for 40 minutes. The product 97, after extensive, 
workup was clean and no further purification is needed. However, once again the yield 
obtained was very low at 25%. The low yield may be a result of decomposition during 
the reaction as a large amount of unidentifiable baseline material was isolated by 
chromatography. 
d) Boron Trichloride (B03) 
Boron-based reagents are particularly versatile for the transformation of primary alkyl 
aryl ethers as the Lewis acidity of the boron and the nucleophilic nature of the ligands 
can be effectively manipulated. The mixture of boron trichloride and tetra-n- butyl 
ammonium iodide (n-Bu4N1) has been shown to be a powerful reagent combination for 
the cleavage of primary alkyl aryl ethers at low ambient temperatures [82]. Although 
boron trichloride on its own does not remove isolated aryl methyl groups at low 
temperatures, the. combination with BCh with n-Bu~ greatly enhances its reactivity. 
n-Bu4NI is a source of iodide. It has been shown that the reaction does not proceed in 
the absence of iodide [82]. 
Substrates that possess multiple Lewis base sites require additional BCh to chelate the 











effect dealkylation provided that there is 1.0 equivalents of additional reagent for each 
additional basic group. Following this, we decided to use 4.5 equivalents in our 
reactions to attempt demethylation of the aryl ether. Using the procedure outlined [82], 
1.5 equivalents of n-Bu4NI and quinacrine 13 in dichloromethane are treated with 4.5 
equivalents ofBCh (lM, CH2Ch) at -78°C and them warmed to O°C. The reaction was 
stirred for 30 min at O°C before being warmed to room temperature and stirred for 24 
hours without any change, Generally, this reagent provides mild, selective ether 
cleavage at low temperature in short reaction times. The reagent could, however, not 
affect ether cleavage on our system. 
e) Boron tribromide (BBr3) 
Boron tribromide is regarded as one of the reagents of choice for dealkylation of ethers. 
BBr3 effects cleavage of the ether linkage without affecting ester groups or double 
bonds. The general reaction procedure stipulates heating the reaction mixture on a water 
bath at approximately 40°C. As such, our first attempt with this reagent was carried out 
at this temperature. 
6, 9 Dichloro-2-methoxyacridine 96 was dissolved in dichloromethane and cooled in an 
ice-bath, 3 equivalents of BBr3 were added dropwise and the reaction was slowly 
allowed to warm to room temperature. The mixture was reacted at 24°C for 24 hours 
before being placed on a water bath and stirred for 12 hours. As there was still no 
change in the reaction, the mixture was brought to reflux for 10 hours. This still had no 
effect on the reaction and yielded only starting materiaL 
Further investigation led to a procedure where the reaction temperature was kept at 
-89°C. The starting ether, 6,9 dichloro-2-methoxyacridine 96 or quinacrine 13, was 
dissolved in dichloromethane and the solution cooled to -89°C in a dry-ice/propanol 
bath. BBr3 (3eq, 1M in CH2Ch) was slowly added to this solution and the mixture 
stirred at -89°C for 1 hour. The solution was then warmed to 17°C and stirred for a 
further 20 hours. Upon completion, the reaction was quenched with ice water and stirred 
for 30 minutes before the product was isolated, without further purification, by filtration 











From the result of this reaction, it seems as if temperature has a major role to play in the 
demethylation of this system. It is well known that boron has a high affinity for and 
forms strong bonds with nitrogen and as the results indicate that at temperatures of DoC 
and above, there is competition between the ether oxygen and the acridine nitrogen for 
the reagent. If complexation does indeed occur at the acridine nitrogen, the Lewis 
basicity of the ether oxygen would be compromised via the inductive pull of electrons 
towards the positively charged acridine nitrogen. This would result in a diminished 
reaction between the ether oxygen and boron tribromide. However, at -89°C, it appears 
as if this competition is minimized and hence retrieval of the product is effected. The 
low temperature seems to affect the kinetics of the reaction perhaps allowing this 
reaction to occur but at a rate so slow that it is almost negligible i.e. complexation of the 
boron tribromide to the nitrogen is under thermodynamic control while complexation to 
























Table 2. Reagents and conditions for attempted demethylation procedures 
Product, 0/0 
Entry Compound Reagent Conditions yield 
1 13 and 96 
TMSCI (3eq), NaI (3.8eq), 
nr' TMSI CH3CN, 24-reflux, N2 
2 96 DIBAH 





hydrochloride Pyr.HCl (5eq), 210°C, 40 min 
4 97 Boron trichloride 
BCh (4.5eq), n-BlLNI (1.5eq), 
nr 
CH2Ch, -78°C -24°C, 24 h 
5 13 Boron tribromide BBr3 (3eq), CH2Ch, 0-24°C nr 
13 and 96 
BBr3 (6eq), CH2Ch, -89-24°C, 
70% 
18 h 
a no reaction occurred 
3.1.5 Synthesis of ether targets, 70-73 
Combinatorial chemistry had emerged as an important tool for the rapid synthesis of a 
large number of structurally diverse small molecule libraries and has become an 
important methodology for expediting the drug discovery process. Alkylation of a 
phenol building block is one approach to the synthesis of large libraries of aryl ethers. 
The ether targets 99-102 were synthesized utilizing the polymer bound base 1, 5, 7-
triazabicyclo [4.4.0.] dec-5-ene (PTBD).[83] (Figure 3.1). This polymer-supported base 
serves a dual purpose in its role as a base for deprotonation of phenols and also acts as a 











used to drive the reaction to completion and products are isolated by simple filtration 
and solvent evaporation. 
Fig 3.1. Structure of the polymer bound base PTBD. 
In a typical reaction procedure, phenol 98 and 0.83 equivalents of the alkyl halide were 
added to a reaction vessel containing the PTBD resin in a small amount of acetonitrile 
(Scheme 3.11). The reaction was shaken vigorously at 24°C until the alkyl halide was 
consumed. The polymeric material was filtered off, washed with acetonitrile and the 
solvent removed. The reaction proceeded well affording the chemically pure product 













Scheme 3.11. Reagents and conditions: (a) alkyl halide (R-X), 2 equiv. PTBD, CH3CN, 24°C, 45-78%. 
Mechanistically deprotonation of the phenol by the polymeric base is the first step. This 











SN2 reaction with the alkyl halide to generate the alkyl ether ArOR. The base also 




BHlAro R-X ... 
Scheme 3.12. Proposed mechanism of action ofPTBD 
3.1.6 Synthesis of target 99 
Wx 
+ ArO-R filter... ArO-R 
Isolation of phenol 97 via dealkylation with pyridine hydrochloride was among the first 
successful dealkylation procedures employed in this work. Attempts to alkylate with 
allyl bromide and PTBD as reagent proved unsuccessful and hence the use of potassium 
carbonate in DMF was investigated. 
a~j 
__ a ____ N~ j 
CI 
CI 
CI Cl b \ j r - ~~'-/ 




97 100 99 
Scheme 3.13. Reagents and conditions: (a) 1.07 equiv. allyl bromide, 10 equiv. K2C03, DMF, 20"C; (b) 
32 equiv. of diaminoalkane, phenol, 90"C, 4h, 61 %. 
To a solution of the phenol 97 in DMF, 1.07 equivalents of allyl bromide was added, 
followed by 10 equivalents of potassium carbonate (Scheme 3.13). The reaction mixture 
was stirred at 18°C for 20 hours to effect alkylation of the phenol yielding 100. Workup 
yielded the crude material which was carried through to the next step, involving 
addition of the side chain present in quinacrine, without further purification. The amine 
precursor for the synthesis of the side chain 101 was envisaged to come from levulinic 














Scheme 3.14. Retrosynthetic analysis for the synthesis of amine 105. 
48 
106 
The oxime-amide intermediate 103 is obtained from the commercially available 
levulinic acid 102 in a two step procedure involving conversion to the acid chloride 
using oxalyl chloride followed by the reaction with diethylamine (Scheme 3.15). The 
ketone functionality of 104 was transformed to the oxime by two methods. The first 
method of refluxing 104 in ethanol with hydroxylamine hydrochloride and sodium 
hydroxide to give 103 in excellent yield. The second method utilized hydroxylamine 
hydrochloride and pyridine under reflux. Although the reaction time was much shorter 
for the latter method, the yield obtained was moderate. In the final step, the oxime and 
amide functionality of 103 were simultaneously reduced by lithium aluminium hydride 
to afford the amine 101 in moderate yield. 
G < N-y-( G 0 a, b 0 






Scheme 3.15. Reagents and conditions: (a) 1.5 eqiv. (COC1)2, O°C, 2b; (b) 2.0 equiv. EhNH. CHzCh, 
20°C, lb, 65%; (c) l.1. equiv. NH20H. HCI, 1.1 equiv. pyridine, EtOH, reflux, 30 min, 58%; (d) 1.6 













3.1. 7 Synthesis of 68-69 
a) Retrosynthetic Analysis 
The Mitsunobu reaction was invoked in the synthesis of ethers 68 and 69. As outlined in 
the retrosynthetic scheme (Scheme 3.16). The alcoholl 05 could be synthesized utilising 
the same chemistry as for the acridine amines 92-95. This procedure is straightforward 
and high yielding. The Mitsunobu reaction of 105 with commercially available 4-
hydroxy acetophenone or 4-hydroxy 2-methoxy benzaldehyde yielded 68 and 69 
respectively. 
Mitsunobu 
68 and 69 CI 
yCfo-i R= 















6, 9, Dichloro-2-methoxy acridine 96 was treated with ethanolamine in the presence of 
phenol in the manner described earlier to yield 105 in excellent yield. The alcohol was 
converted to the ether using standard Mitsunobu reaction conditions (Scheme 3.17). 
This reaction is believed to proceed through: (a) addition of triphenylphosphine to 
diethylazodicarboxy1ate (DEAD) to give a quarternary phosphonium salt, (b) the 
phosphonium salt is protonated in the presence of the R group, (c) the alcohol activation 
group involves the transfer of the phosphorous group to the alcohol to form the 











oxyphosphonium by the deprotonated R group to give 68 and 69 and 













N r --.....,r 
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Scheme 3.17. Reagents and conditions: (a) 32 equiv. diaminoalkane, phenol, 90°C, 4h, 80%; (b) 1.0 
equiv. PPh3, 1.0 equiv. DEAD, 1.0 equiv. 4-hydroxy-2-methoxy-benzaldehyde or 4-
hydroxybenzaldehyde, 0-20oe, 2411, 26-58%. 
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4. 1 CHEMICAL SYNTHESIS 
4.1.1 Synthesis of sulfonamides 
4.1.1.1 General method for sulfonamide synthesis 
51 
The amines were treated with 1 A equivalents of 2-naphthalene sulfonyl chloride and 2 
equivalents of triethylamine. After 14 hours the reaction was complete. Water was used 
to quench the reaction. In the case of formation of a solid precipitate upon addition of 
the water, simple filtration yielded the desired products. However, in those cases where 
oils were obtained, these were extracted with ethyl acetate. In this case, recrystallization 
of the resulting material yielded the product. The reaction conditions are illustrated in 
Scheme 4.3. 
4.1.1.2 Synthesis of 78 and 80 
a) Retrosynthetic analysis 
As outlined in the retrosynthetic scheme (Scheme 4.1), the benzylated products 78 and 
80 could be synthesized by direct benzylation of the sulfonamide nitrogen. This is a 
simple procedure requiring a base in the form of potassium carbonate and the 
benzylating agent in solvent. The sulfonamides were synthesized as described above by 
addition of the sulfonyl chlorides to the respective amines. The amines were synthesized 
from the commercially available 4, 7 dichloroquinoline 106 in a nucleophilic 

















Scheme 4.1. Retrosynthetic scheme for 78 and 80. 
b) Synthesis 
Amines 107-110 were synthesized directly from commercially available 4, 7 
dichloroquinoline 106 (Scheme 4.2) and the appropriate diaminoalkane to yield 
quinolines of various methylene spacer lengths in the side chain. Amines 108 and 109 
were utilized in these reactions. These were subjected to the conditions described above 
for the synthesis of the sulfonamides 77 and 79. To a solution of the sulfonamides in 
DMF, l.1 equivalents of benzyl bromide was added, followed by 10 equivalents of 



















Scheme 4.2. Reagents and conditions: (a) 4.5 equiv. of diarninoalkane, 80-l30aC, 4h, 77-91%; (b) l.4 
equiv. of 2-naphthalene sulfonyl chloride, 2 equiv. of Et3N, DMF, 20°C, 18h, 72-84%; (c) 1.1 equiv. of 
BnBr, 10 equiv. ofK2C03, DMF, 24h, 20°C, 48-60% 
4.1.1.3 Synthesis of75 
The benzylated sulfonamide 75 was synthesized in precisely the same manner as 78 and 
80. The sulfonamide 74 was synthesized as above from primaquine 16 which is 
commercially available in the form of primaquine diphosphate. 
117 
Scheme 4.3. Reagents and conditions: (a) 1.4. equiv. of 2-naphthalene sulfonyl chloride, 2 equiv. Et3N, 
DMF, 20ac, 18h, 96%; (b) 1.1. equiv. ofBnBr, 10 equiv. ofK2C03, DMF, 24h, 20aC, 60%. 
4.1.1.4 Synthesis of 76,81-84 
Again this series of sulfonamides was synthesized as outlined in the general method 











dichloroquinoline 106 while 76 was synthesized from starting material primaquine. 
Yields are indicated below. 
Table 3. Table showing substituents (R) from sulfonamides and their synthetic yields 
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The synthesis of the piperazine quinoline 117 from which compounds 83 and 84 were 
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106 111 
Scheme 4.4. Reagents and conditions: (a) 5 equiv. of piperazine, 1.5 equiv. of Et3N, 0.3 equiv. KZC03, 











4.1.1.5. Synthesis of 85 and 86 
The synthesis was achieved through the tosylate intennediate 112 (Scheme 4.5) which 
was obtained from the 4, 7 dichloroquinoline 106 in a two-step procedure. The alcohol 
120 was synthesized in the same manner as the amines 107-110 described above. In an 
attempt to synthesize 85 and 86 we attempted to ascertain whether the synthesis of a 
tosylate or iodide intermediate would be more feasible. The tosylate 112 was 
synthesized from tosyl chloride and triethylamine. The reaction proceeds from 0 to 
20°C in 1 hour. The second procedure which was attempted involved the use of iodine, 
imidazole and triphenylphosphine to produce the iodide 113. The reaction proceeded at 
20°C for 5 hours with a very extensive workup involving filtration through celite. Since 
the former method gave a better yield and was much more convenient in tenns of 
workup, that procedure was adopted. Reaction with either 3-dimethyl-l-propylamine or 
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Scheme 4.6. Reagents and conditions: (a) 4.5. equiv. of ethanolamine, 90-140"C, 4h, 36%; (b) 2.2 equiv. 
ofEt3N, CHzCh, 0-20"C, 1h, 39%; (c) 2 equiv. of amine, CH3CN, reflux, 24h, 37-66% 
4.1.2 Synthesis of bisquinoline ureas 87 and 88 
a) Retrosynthetic Analysis 
Synthesis of target compounds 87 and 88 was achieved through the carbamate 90 which 
was synthesized, in a two-step procedure, from 4, 7 dichloroquinoline 106. 107 was 
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Compound 107 was transformed to the carbamate 90 by reaction with phenyl 
chloroformate at aoc in the presence of DMF with dichloromethane as solvent. In the 
final step the carbamate was converted to the symmetrical urea (n=2), 88 and the 
unsymmetrical urea (n=3), 87 by reacting it with the amines 107 and 110 respectively. 
106 107 90 
c 
85/86 
Scheme 4.8. Reagents and conditions: (a) 4.5 equiv. diethylamine, 80°C, 4h, 77%; (b) 1.0 equiv. of 
phenyl chlorofonnate, 1.0 eqniv. DMF, CH2Ch, O°C, 5h, 58%; (c) 1.4 equiv. of amine, THF, 20-60°C, 
26h, 65-74%. 
c) Mechanism of reaction 
Nucleophilic attack of the DMF on the carbonyl centre of phenyl chloroformate 
produces the intermediate 115. Both groups attached to the carbonyl group on 115 are 
good leaving groups but the regeneration of DMF is the driving force which favours 
expulsion of the iminium ion-enol ether group. This then produces DMF and the desired 
carbamate product (Scheme 4.9). The reaction proceeds at aoc as the intermediate 115 
is unstable above this temperature. Loss of carbon dioxide occurs easily at room 














Scheme 4.9. Mechanistic interpretation of carbamate formation and room tempemture effects 
4. 1.3 Synthesis of urea 89 
Synthesis was carried out in precisely the same manner as described for 87 and 88. The 
synthesis was carried out in a two-step procedure. The first step involved formation of 
the carbamate 91 from the commercially available 3-dimethylamino-l-propylamine 
116. Transformation of the carbamate to the urea took place in the presence of amine 
109. The synthesis of 89 was attempted with the use of two different solvents in an 
effort to improve the reaction yield. The method utilizing DMF resulted in a better yield 





















Scheme 4.10. Reagents and conditions: 1.0 equiv. of phenyl chlorofonnate, 1.0 equiv. DMF, CH2Ch, 












BIOLOGICAL RESULTS AND DISCUSSION 
5.1 INHIBITORS OF TRYPANOTIDONE REDUCTASE 
5.1.1 Inhibition activity of derivatives 55-57, 59-62, 63, 64, 66, 67-69 and 87-89 
The data in Table 4 shows the activity of these derivatives with respect to inhibition of 
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Table 4: Inhibition of trypanothione reductase and glutathione reductase by quinacrine and analogues. 
Number of Trypanothione Glutathione 
Compound Methylene Reductase Reductase 
Selectivity 
Indexa 
Groups, n = IC5o, j..t.M ICso, J.lM 
Quinacrine 13 N/A 133 ± 11 > 1,000 > 7.5 
55 2 5.9 ± 0.6 9.9 ± 0.4 1.7 
56 3 3.3 ± 0.3 27.2 ± 0.6 8.2 
57 4 5.0 ±0.2 13.9 ± 1.3 2.8 
59 2 19.3 ± 1.0 27.2 ± 0.6 1.4 
60 3 13.1±0.7 44.7 ±4.4 3.4 
61 4 15.5 ± 0.8 55.8 ± 2.6 3.6 
62 6 11.4 ± 0.7 17.1±3.1 1.5 
63 2 19.6±0.2 nd nd 
64 4 11.7±0.5 nd nd 
66 6 9.5 ±0.5 nd nd 
67 2 38.9 ± 1.2 nd nd 
68 2 173 ± 1 nd nd 
69 2 104± 9 nd nd 
87 2 7.6 ± 0.1 nd nd 
88 3 lOA ± 0.3 nd nd 
89 3.2±0.2 nd 
aratio IC50 GRlICso TryR 
The enzyme assays were performed essentially as described before [86]. Recombinant 
T.cruzi TryR (128 mU) was assayed using a Beckman DU640 spectrophotometer in 40 
mM HEPES, pH 7.5, 1 mM EDTA and 200 J.lM NADPH at 25°C followed by the 
addition of 100 j..t.M Try[SHh. Human glutathione reductase, purified from human 
erythrocytes (42.3 mU), was analysed in a similar manner and under identical 
conditions followed by addition of glutathione disulfide (100 j..t.M). Enzyme mixtures 
were preincubated with NADPH (10 min at 25°C) before the addition of varying 



















As can be seen from Table 4, the sulfonamides (55-57), ureas (59-62) and amines (63, 
64, 66) were generally superior to quinacrine in inhibiting TryR This has been 
demonstrated graphically for the sulfonamides 55-57 and ureas 69-62 (figure 5.2). The 
sulfonamide series was superior to the amine series which in tum was superior to the 
urea series. The superior nature of the sulfonamide series may be attributed to a more 
hydrophobic naphthalene moiety in 55-57 as compared to the benzyl moiety in both 59-
62 and 63, 64, 66. The amine series 63, 64, 66 is marginally better at inhibiting TryR 
than the urea series 59-62. Despite the superior inhibitory activities of the sulfonamide 
and urea derivatives, selectivity against the human enzyme, glutathione reductase. The 
loss of the positive charge (from the terminal tertiary amino group) in moving from 
quinacrine to the new derivatives could account for this loss in selectivity [87J. The three 
and four-carbon methylene spacer length appears to be optimum for the inhibition of 
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Compounds 67-69 show decreased inhibitory activity against TryR as compared to the 
other derivatives discussed. The methylene spacer in this series was kept constant at two 
carbons and the terminal group functionality manipulated. The most polar terminal 
group in the series is that of 68 which shows the least inhibitory activity. It is closely 
followed by 69, whose only structural difference to 68 is the loss of a methoxy group. 
This suggests that an increase in the hydrophobic nature of the extended side chain has 
an effect on the inhibitory activity of the molecule. Compound 67 has the greatest 
inhibitory activity within the series. It is interesting to note that upon moving from the 
hydroxy group in 67 to the ethers of 68 and 69, there is a marked decrease in the 
inhibition ofTryR. 
Compounds 87-89 showed general superiority to quinacrine in inhibiting TryR with 89 
showing the greatest inhibition in the series. Comparing 88 and 89, the only structural 
difference is the absence of the quinoline moiety in 89 where it has been replaced with a 
dimethylamine. This appears to have a marked effect on TryR inhibition. 
5.1.2 Inhibition activity of ether derivatives 70-73 
The model that quinacrine binds to two hydrophobic pockets in the active site of the 
enzyme TryR, was further investigated by substituting the methyl group of the methoxy 
group with longer alkyl chains 70-73. As can be seen from Table 5, the effect of 
substituting this methyl group renders the derivatives more superior to quinacrine in 
inhibiting TryR. Effectively, increasing the number of carbons in the side chain results 
in a greater inhibitory activity of the molecule. Consequently, 73, with five carbons in 
the side chain, is superior to the other compounds in the series. The three and four 
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133 ± 11 
50.7 ± 2.2 
39.0 ± 0.9 
41.4± l.3 
30.4 ± 0.7 
65 
5.2 ANTIPROTOZOAL ACTIVITY RESULTS OF SELECTED COMPOUNDS 
55-57,59-62 and 87-89 
Due to factors beyond our control, some compounds were not tested within the time 
frame of the project. Although P. falciparum was not a target of the current project, 
literature reports on the antimalarial activity of quinacrine and chloroquine analogues 
prompted us to evaluate some compounds in this regard. Compounds were tested in 
vitro for activity against amastigote forms of Leishmania donovani (cultured in murine 
macrophages), amastigote forms of Trypanosoma cruzi (cultured in murine 
macrophages), and the bloodstream form trypomastigote Trypanosoma brucei 
rhodesiense. Experimental details have previously been described [38]. For Plasmodium 
falciparum, all compounds were tested against the chloroquine-sensitive strain (3D7) 
and the most potent also tested against a chloroquine-resistant strain (K1). The whole 
cell inhibition assay of Plasmodium falciparum growth in human red blood cells was 
carried out in a 48h eH]-hypoxanthine incorporation assay [88,89]. Potential toxicity of 
the quinacrine derivatives was determined against the KB cell line in comparison to 
podophyllotoxin. The data are presented in Table 6. Data for standard control drugs are 
included for comparative purposes. 
Considering the sulfonamides (55-57) and ureas (59-62): compounds generally showed 
significant activity against L. donovani with compounds 56, 60, and 61 being the most 











the exception of urea compounds 61 and 62 which showed good activity against T. 
cruzi, the rest of compounds displayed weak to no activity at the test concentrations. 
As with the inhibition of TryR and activity against L. donovani, compounds 56, 60, and 
61 showed the best activity against T. brucei. The same picture is more or less true for 
P. jalciparum where the compounds showed the greatest activity, compound 60 being 
most noteworthy. This compound was 4 and 10 times more active than chloroquine 
against 3D7 and Kl strains respectively. The fact that 60 is less active against the Kl 
than the 3D7 strain suggests haem polymerization as a target, like the 4-
aminoquinolines [90]. This in turn suggests cross-resistance with chloroquine. The 
compounds that were active against L. donovani and T. cruzi were also toxic to KB cells 
at the same concentrations, indicating a lack of selectivity against these parasites. 
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Chloroquine 0.002 0.15 
55 5.8 >30 0.47 0.025 nde 2.7 
56 1.9 23.9 0.078 0.010 nd 0.4 
57 3.3 >30 0.12 0.033 nd 0.4 
59 10.7 >30 0.42 0.069 nd 4.l 
60 1.9 22.0 0.083 0.0005 0.015 0.7 
61 1.9 <1 0.043 0.0013 nd 0.8 
62 5.8 6.8 0.46 0.14 nd 4.3 
87 >30 >30 14.72 <0.1 0.55 >300 
88 >30 >30 13.37 <0.1 0.56 >300 
89 >30 >30 >30 9.6 0.55 >300 











The bisquinoline urea series (87-88) and urea 89 generally did not show any significant 
activity against L. donovani, T. cruzi. T brucei or P. Jalciparum Kl. This data did not 
correlate with the data for inhibition ofTryR in Table 4. Factors such as cell penetration 
and metabolism may play in explaining this lack of correlation. It is also important to 
note that for the intracellular L. donovani and T. cruzi amastigotes, the drug needs to 
pass through the macrophage to reach the amastigote. As a result, selective toxicity in L. 
donovani and T cruzi is more difficult to achieve than for T brucei. 87 and 88 showed 
the greatest inhibition against the P. Jalciparum 3D7 strain. Both are less active against 
the Kl strain than the 3D7 strain, once again suggesting haem polymerisation as a 
target. 
5.3 ASSESMENT OF IN VIVO GROWTH INHmmON ACTIVITY IN CQ-
SUSCEPTIBLE P. BERGHEI ANKA RODENT MODEL 
The in vivo activity of compounds 87-89 against malaria parasites was tested by 
determining their ability to protect mice from the lethal effects of P. berghei infection. 
These compounds were injected intraperitonealy at 25 mg/kg once a day every day. 
Table 7:Response of P. berghei to selected quinoline derivatives in comparison with chloroquine. 
Dose (mg / kg) Schedule Mean Parasitemia Mean Survival 
Group 
Time (days) 
Control 16.99 ± 1.16 5.00 ± 0.00 
Chloroquine 10 x 4 i. p. 0.00 28 ± 0.00 
87 25 x4 i. p. 12.59 ± 0.79 6.00 ± 0.45 
88 25 x 4 i. p. 12.27 ± 0.55 9.0 ± 0.00 
89 25 x 4 i. p. 0.00 26.40 ± 2.23 
As can be seen in Table 7 these compounds reduced the level of parasitemia in mice 
infected with P. berghei. However, only 89 yielded a reduced parasitemia comparable 
to that ofCQ. 
The control mice died after 5 days post infection but the 87 treated mice lasted for 6 
days, the 88 treated mice lasted for 9 days and the 89 treated mice lasted for 26.40 days. 
Again 89 is comparable to the survival time of the CQ treated mice at 28 days. The 











were not completely cleared Presumably, another scheme of administration of the drugs 
could be required for th best resul ts. A graphical representation of the data (figure 5.4) 
indicates how the tested compounds influenced the course of a well-established 
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Figure 5.4. Effect of compounds 87-89 on the level of parasitemia in mice parasitized by P. berghei. 
5.4 MODULATION OF HUMAN MAMMARY CELL SENSITIVITY TO 
PAC LIT AXEL 
In order to establish the intrinsic anticancer activity, the derivatives were first tested 
again t a paclita. el-sen itive (LCC-WT -Human brea t carcinoma) and pacl itax 1-
resistant (LCC6-MDR-MDRI transfected) cell lines[91 1. Cells were seeded at 2000 
c II Iwell in 96-well plat s in compi te medium-RPMI-1640 containing 5% rcs, 5% 
Nuserum IV, 2 mM L-glutamine and 10 mM HEPES. Following overnight incubation, 
compounds w r s Iubiliz d in 100% DMSO, dilut d in ompl te medium and added to 
cell plates. After 72 hours, cells were fixed, stained and total protein/well was 
detennined. Compound concentration that inhibited growth by 50% was detennined and 
reported as ICso. The data are summarised in Table 8. The compounds generally showed 
none or v ry w k cytotoxic ity at at st concentration of 10 )lM (1)lM for 88 and 89) in 
both cell lines. The only exception was compound 80 which was found to be cytotoxic 













78: n = 4 
80: n = 6 
89 
Figure 5.5. Structures of derivatives tested as MDR reversal agents 
69 
Table 8: Cytotoxicity of Quinolines 81,82, 85 and 87 Against Sensitive and Resistant Human Breast 
Cancer Cells 
Compound ICso (J.1M) +/- S.D. %Growth Inhibition at 10 J.1M 
LCC6-WTa LCC6-MDRa LCC6-WT LCC6-MDR 
Paclitaxel 27 0.008 ± 0.001 0.612 ± 0.021 
81 >10 >10 16 8 
82 >10 >10 0 8 
85 >10 >10 6 3 
87 l.7 ± 0.09 2.0 ± 0.24 
95 11 ± 90 >10 
96 >10 >10 
aLCC6-WT -hmnan breast carcinoma; LCC-MDR -MDRI transfected line 
The compounds were then co-administered with paclitaxel at four different 
concentrations as shown in Table 9. Paclitaxel recovered 96-99% of its efficacy against 
the resistant human breast cancer cells when compounds 74,75, 78 and 80 were co-
administered at a concentration of 5 J.1M. However, when co-administered with 
paclitaxel at a concentration of 1 J.1M, only compound 80 exhibited 99% MDR reversal 
activity. Based on this, and the result with compound 78 in comparison with the results 











supenor to the primaquine senes 74 and 75. It is noteworthy that primaquine 
compounds 74 and 75 are racemates and the biological activity may reside in one 
enantiomer only. As such higher potency may be expected from the appropriate single 
enantiomer. The bisquinoline urea 88 and the urea 89 display no significant activity. 
Table 9: Modulation of Human Mammary Cell Sensitivity to Paclitaxel by Quinolines 74, 75, 78 and 
80 
Compound Concentration, {LMt ICso (nM) %ICso Reduction 
LCC6-MDR 
Paclitaxel 0 
Paclitaxel + (74) 5 13 97 
Paclitaxel + (75) 5 19 96 
Paclitaxel + (7S) 5 2.7 99 
Paclitaxel + (SO) ndb nd nd 
Paclitaxel + (74) 1 353 36 
Paclitaxel + (75) 1 249 55 
Paclitaxel + (7S) 1 164 70 
Paclitaxel + (SO) 1 6.2 99 
Paclitaxel + (SO) 0.3 254 54 
Paclitaxel + (80) 0.1 338 39 
Paclitaxel + (8S) 1 545 ± 15 17 
Paclitaxel + (89)b 1 643 ± 29 2 
"No growth inhibition was seen at this concentration of reversal agent; ENot detennined due to 
cytotoxicity at 5 flM 
bpaclitaxel ICso 653 ± 18 
5.5 COMMOM PHARMACOPHORE FOR 78, 80 TAXANE MDDR AGENTS, 
AND A PGP PHOTOAFFINITY LABELLING TAXOID 
Since antimalarial drug analogs, 74, 75, 78 and 80 exhibited substantial MDRR activity 
against LCC6-ADR when co-administered with paclitaxel, it was reasoned that there 
might be a common pharmacophore for these sulfonamide based compounds and 
taxane-based MDR reversal agents that were developed earlier. Accordingly, 
compounds 78 and 80 as well as taxane MDR reversal agents (tRAs), SB-RA-30001 
and SB-RA-31012, [92] and photoaffinity labeling taxoid CH}-SB-T-51 11 [93j for a 
molecular modelling study (Figure 5.6.), and investigated common structural features 

















Figure 5.6. Structures of taxane MDR reversal agents (mAs) SB-RA 310 12 and photoaffinity labelling 
taxoid {3H}-SB-T -5111. 
The molecular modelling was performed on a Silicon Graphics O2 workstation using 
two programs: SYBYL 6.4 and InsightII 2000. The quinoline sulfonamide structures, 78 
and 80 were constructed in SYBYL 6.4 and energy-minimized (Tripos force field, 
charges calculated by the Gasteiger-Huckel method). The lowest energy conformations 
of SB-RA-30001 and SB-RA-31012, and photoaffinity taxoid CH}-SB-T-5111 were 
obtained using SYBYL 6.4 by modifying the X-ray structure of paclitaxel and 
minimizing the resultant conformers. The template forcing was performed using the 
InsightII 2000IDiscover Module (tRAs or the taxoid as the template and 78 or 80 as the 
mover) using constant valence force field (CVFF). The resultant conformers of 78 and 
80 were energy-minimized so that the energies of these conformers were within the 5-
kcallmol range from that of the lowest energy conformation. Then, these minimized 
conformers of 78 and 80 were overlaid with the tRAs and the taxoid. The overlay 
results are shown in Figure 5.7. 
As Figure 5.7(a) shows, the two naphthyl moieties of 80 and the phenyl group of the C-
2 benzoate as well as the naphthalene group of the C-7 acyl moiety of SB-RA-3000l 











high MDR reversal activity with paclitaxel (97.5% at 1 11M against human breast cancer 
cell line MCF7-ADR)[921. As compared to 80, the overlap of the naphthalene moiety of 
78 with the naphthalene group of the C-7 acyl moiety of SB-RA-3000 1 is only partial. 
This observation is consistent with the difference in activity of78 and 80. Figure 5.7(b) 
shows the overlay of 78, 80, and SB-RA-31 0 12 that is a highly potent MDRR agent for 
paclitaxel (99% reversal activity at 1 11M and 92% at 0.1 11M against LCC6-ADR)[92I. In 
this case, one of the aromatic ring of the naphthyl moiety of 80 overlaps with one of the 
phenyl group of the benzophenone moiety of SB-RA-31012, but 78 does not have 
overlap in this part of the molecule. As Table 6 shows, 80 exhibits high potency (99% 
reversal activity) at 111M, but the potency drops to 33% at 0.1 11M. This might be due 
to the fact that the methylene chain of 80 is not long enough to reach more preferable 
hydrophobic binding site to which the benzophenone moiety of SB-RA-31012 binds. 
Figure 5.7(c) shows the overlay of 78, 80, and eH}-SB-T-5111 that has been used for 
the photo affinity labeling of Pgp [93J. As anticipated, the overlaps in the C-2 benzoate 
moiety and the tethered benzophenone moiety at C-7 with 78 and 80 are essentially the 
same as the case of SB-RA-31012. It should be noted that the phenyl group of the 
benzylamino moiety of 78 and 80 is located in the "hydrophobic clustering" region of 
the taxoid. In addition, the phenyl and the naphthyl groups are apparently clustered 
through aromatic 1L-1L interaction. As discussed above, the molecular modelling study 
has disclosed a probable common pharmacophore for these structurally very different 
classes of compounds, which provides a good rationale for the excellent MDR reversal 










Fig 5.7: Molecular modelling graphics of quinolines overlaid with tRAs and photoaffinity 
labelling taxoid. 
5.6 Summary of results 
73 
A series of sulfonamides 55-57, ureas 59-62 and ammes 63, 64, 66 analogues of 
quinacrine generally show superior activity (relative to quinacrine) against TryR. 
Although sulfonamide derivatives were the most active series inhibiting TryR, this trend 
did not correlate with the in vilro activities against L. donovani, T cruzi, and T brucei. 
Urea compounds in particular showed significant activity in vilro against all four 
parasites. Although T cruzi appears to be the least sensitive compared to L. donovani, it 
is noteworthy that compounds display activity against these intracellular Tcruzi 
parasites where the drug must cross the macrophage to reach the amastigote (tissue form 
of the parasite pliced near the cell nucleus). The mode of action of these compounds is 
not clear and merits further investigation. Although series 67-69 displayed activity 
better than that of quinacrine, the results were not comparable to the aforementioned 
series of compound::;. The compounds 70-73 are a good indicati n that a longer alkyl 
group to replace the methyl of the methoxy group renders an increase in TryR inhibition 
as compared to quinacrine. This is an important piece of new information which could 
be exploited further in the use of such compounds as probes for the investigation of the 











The bisquinoline ureas 87-88 were superior to quinacrine at inhibiting TryR and the 
urea 89 showed potent inhibitory activity as well. Both series' however did not display 
any significant anti protozoal activity apart from the activity exerted against the P. 
jalciparum 3D7 strain. This result merits further investigation. These compounds were 
also ineffective as chemosensitizers in restoring the sensitivity of cancer cells to 
paclitaxel. Despite not having any significant in vitro activity, 89 has shown good in 
vivo activity on a level comparable to that of CQ. However, toxicology studies need to 
be carried out to determine the cytotoxicity of 89 to mammalian cells. As inhibitors of 
TryR, 87-89 were more 13-41 times more active than quinacrine. 
Although the bisquinoline ureas did not show any real promise as chemosensitizers, we 
have shown the potential of quinoline-based compounds 78 and 80 to chemosensitize 
cancer cells to paclitaxel. These compounds are non-cytotoxic and, as such, they hold 
promise. The quinoline series was found to be superior to the primaquine series 74 and 
75. Once again, it is important to note that the biological activity of 74 and 75 may 
reside in one enantiomer. It needs to be further investigated whether a higher potency 













6. 1 General: 
Melting points were determined on a Reichert-Jung Thermovar and a Fischer-Johns hot 
stage microscope and are uncorrected. Proton nuclear magnetic resonance spectra were 
recorded using trimethylsilane as an internal standard on a Varian VXR-200 (200MHz), 
Varian Mercury (300MHz) or a Varian Unity Spectrometer (400MHz). Carbon -13 
nuclear magnetic resonance spectra were determined on the same instruments at 50, 75 
or 100MHz (using trimethylsilane as an internal standard). Infrared spectra were 
recorded in solutions specified using a Perkin Elmer Paragon 1000 FT -IR or a Satellite 
FT-IR spectrometer. Elemental analyses were performed using a Fisons EA 1108 
CHNS-O instrument. Mass spectra were recorded on a VG micromass 16F spectrometer 
operating at 70eV with an accelerating voltage of 4kV. Accurate masses were 
determined using a VG-70E spectrometer at the Cape Technikon. 
All reactions were monitored by thin layer chromatography using aluminium-backed 
silica gel 60F254 plates (Merck). The plates were visualised by a combination of 
ultraviolet light (254nm) and either anisaldehyde spray [prepared from a 2.5% solution 
of p-methoxybenzaldehyde (20cm3) and 18 M sulphuric acid (1 cm3)] or cerium (IV) 
ammonium sulfate in 8 M sulphuric acid and baking at 200°C. Column chromatography 
was carried out on silica gel (Merck Kieselgel 60: 70-230 mesh for gravity and 230-400 
mesh for flash chromatography). 
All solvents used were dried by the appropriate technique[94]. Tetrahydrofuran and 
diethyl ether were dried over sodium wire prior to use using benzophenone as indicator. 
Triethylamine was dried over and distilled from calcium hydride and it was stored over 
potassium hydroxide pellets. Dichloromethane was dried over phosphorous pentoxide 
and distilled. Solvents not mentioned which were used in reactions were anhydrous 











The following numbering system was used to assign aromatic protons in the proton 






CI 9 N 
8 1 CI 











6.2 PROCEDURES FOR ACRIDINE ANALOGUES 
CI 
General procedure for preparation of acridine 
amines 92-95 - A mixture of 6,9-dichloro-2-
methoxyacridine (10.3 mmol), diaminoalkane (330 
mmol) and phenol (0.78 glmmol) was heated at 90°C for 
4 h[731. The resulting yellow mixture was cooled to room temperature. Then water (400 
cm3) was added yielding a yellow precipitate. This was isolated by suction filtration and 
dried in a vacuum dessicator to yield the desired amine. 
Diaminoalkanes used: 1, 3 diaminopropane, 1, 4 diaminobutane, 1, 6 diaminohexane 
and 1, 3 diaminoethane 
N1_ (6'-chloro-2'-methoxyacridin-9'-yl) propane-l, 3-diamine (92). - (2.71 g, 95%) 
as yellow crystals, mp 89-92°C (from EtOAc/pet ether) (lit 98-102P31t; Rf 0.47 
~OH: MeOH, 1 :9) IR (Nujol): vrnaJcm-1 3700 (NH2), 3050 (C=C) and 1620 (C=N); 
OH (400 MHz, CDCh) 1.83 (2H, m, ArNHCH2CHr ) 3.07 (2H, t, J 6 Hz, 
ArNH(CH2hCH2NH2), 3.91 (3H, s, OCH3), 3.93 (2H, t, J 6.0 Hz, ArNHCH2-), 7.19 
(lH, dd, J2.4 and 9.2 Hz, H3'), 7.34 (1H, d, J 2.8 Hz, H5'), 7.38 (lH, dd, J 2.8 and 9.2 
Hz, HT), 7.95 (1H, d, J9.2 Hz, H4'), 8.01 (lH, d, J2.4 Hz, HI') and 8.09 (IH, d, J9.2 
Hz, H8'); oe (100 MHz, CDCh) 32.5, 41.4, 50.8, 55. 5, 100.1, 114.7, 117.1, 123.4, 
124.0, 125.1, 127.9, 131.2, 134.6, 146.6, 148.9, 150.4 and 155.5; HRMS (El) mlz 
315.11363 (Mt; C17H18ClN30 requires 315.11384; Anal. Calc for C17H 1SClN3.3/4 H20; 
C, 62.1%; H, 5.5%; N, 12.7%; Found C, 62.5%; H 5.7%, N 12.5%. 
t This melting point was obtained after repeated recrystallization 
N1_ (6'-chloro-2'-methoxy-acridin-9'-yl)-ethane-l, 2-diamine (93). - (1.43 g, 95%) as 
yellow crystals, mp 81-83 QC (from EtOAclpet ether); Rf 0.33 ~OH: MeOH, 1:19); 
IR (Nujol): Vrnax (CH2Ch)/cm-
1 3700 (NH2), 3050 (C=C) and 1620 (C=N); OH (400 
MHz, CDCh) 3.01 (2H, t, J 5.6 Hz, ArNHCH2CH2-), 3.71 (2H, t, J 5.6 Hz, ArNHCHr 
), 3.95 (3H, s, OCH3), 7.29 (H, dd, J 2.4 and 9.6 Hz, H3'), 7.38-7.42 (2H, m,), 7.99 (H, 
d, J9.2 Hz, H4'), 8.05 (H, d, J2 Hz, HI') and 8.13 (H, d, J8.8 Hz, H8'); Dc (50 MHz, 











144.4, 148.1, 150.3 and 155.9; HRMS (El) mlz 301.09972 (Mt, C16H16CIN30 requires 
301.9819; Anal. Calc for C16H16CIN30.3/4 H20; C, 61.0%; H, 5.1%; N, 13.4%; Found 
C, 59.7%; H, 5.4%, N, 13.1%. 
N1_ (6'-chloro-2'-methoxy-acridin-9'-yl-butane-l, 4-diamine (94). - (1.11 g, 74%) as 
yellow crystals, mp 51-53°C (from EtOAclpet ether); Rf 0.24 (NH40H: MeOH, 1:9), 
Vmax (CH2Ch)/cm-
1 3700 (NH2), 3050 (C=C) and 1620 (C=N); OH (400 MHz, CDCh) 
1.61 (2H, quin, J 4 x 5.4 Hz ArNHCH2CH2 -), 1.83 (2H, quin J 4 x 7.4 Hz, ArNH 
(CH2)2CHr), 2.79 (2H, t, J 6.8 Hz, ArNHCH2-), 3.74 (2H, t, J 7.2 Hz, ArNHCH2-), 
3.95 (3H, s, OCH3), 726-7.29 (2H, m), 7.42 (H, dd, J 2.8 and 6.4 Hz, H7'), 7.98-8.06 
(3H, m);Oe (100 MHz, CDCh) 29.0, 30.8, 41.5, 50.7, 55.5, 99.5, 114.4, 115.8, 117.9, 
1242, 124.3, 125.6, 128.2, 131.5, 134.7, 146.8, 149.9 and 155.9; HRMS (El) m/z 
329.13011(Mt, C18H20Cl N30 requires 329.12949; Anal. Calc for C18H20CI N30 .3/4 
H20; C, 63.0%; H, 5.8%; N, 12.2%, Found C, 62.9% H 5.7%, N 11.9%. 
N1_ (6'-chloro-2'-methoxy-acridin-9'-yl)-hexane-l, 6 diamine (95). - (1.43 g, 95%) as 
yellow crystals, mp 54-57°C (from EtOAc/pet ether); Rf 0.27 (NH40H: MeOH, 1 :9); 
Vmax (CH2Ch)/cm-
1 3700 (NH2), 3050 (C=C) and 1620 (C=N); OH (400 MHz, CDCh) 
1.35-1.46 (4H, m, 2 x CH2), 1.75 (4H, m, 2 x CH2), 2.66 (2H, t, J 6.4 
ArNH(CH2)5CH2NH2), 3.68 (2H, t, J7.2 Hz, ArNHCHr ),3.95 (3H, s, OCH3), 7.18 (H, 
d, J 2.6 Hz, H5'), 7.29 (1H, dd, J 2.0 and 9.2 Hz, H3 1), 7.41 (1H, dd, J 2.6 and 9.2 Hz, 
H7'), 7.98 (H, d, J 9.2 Hz, H4'), 7.99 (H, d, J 9.2 Hz, H8') and 8.06 (1H, d, J 2.4 Hz, 
HI'); Oe (100 MHz, CDCh) 26.7,31.8,33.5,42.0,50.7,55.5,99.2,115.7, 115.9,118, 
124.0,124.4, 124.6, 128.3, 129.5, 131.5, 134.8,148.4, 149.7 and 156.1; %. HRMS (EI) 
mlz 357.16151 (Mt, C2oH24CIN30 requires 357.16079; Anal. Calc for 
.C20H24ClN302H20; C, 60.9%; H, 6.1%; N 10.7%, Found C, 60.7%; H, 6.2%, N 10.7. 
CI 
General procedure for preparation of 
sulfonamides 55-58 - 2-Naphthalene sulfonyl 
chloride (1.78mmol) was added to a solution 
of diamine (l.27mmol), triethylamine 











dimethylformamide (1.97cm3/mmol) in a vial. The resulting mixture was shaken for 14 
hat 20°C[951. Water (0.2 cm3/mmol) was added to quench the reaction and the resultant 
mixture was extracted with ethyl acetate (0.1 cm3/mmol). The organic residue was 
removed by pipette, dried with magnesium sulfate and the solvent removed in vacuo. 
Alternatively, the resultant yellow precipitate was isolated by filtration. The resulting 
yellow crystals were recrystallized from ethyl acetate/pet ether to yield the sulfonamide. 
Diamines used: 92-95 
Naphthalene-2-sulfonic acid [2-(6' -chloro-2' -methoxy-acridin-9' -ylamino )-ethyl]-
amide (55). - (0.35 g, 93 %), mp 129-131°C (from MeOH); Rf 0.39 (MeOH: CH2Ch, 
1:9); Vmax (DMSO)/cm-
1 3311 (N-H) and 1333 (S02NH); OR (300 MHz, DMSO-d6) 3.45 
(2H, t, J2.7 Hz, ArS02NHCHr ), 3.89 (3H, s, OCH3), 4.11 (2H, t, J 5.7 Hz, ArNHCHr 
),7.26 (H, dd, J2.1 and 9.3 Hz, H3'), 7.46-8.37 (12H, m); Oe (75 MHz, DMSO-~) 30.7, 
35.7, 42.5, 48. 7, 55.7, 116.0, 121.9, 122.3, 122.8, 123.9, 124.0, 125.3, 126.2, 126.3, 
127.1, 127.3, 127.4, 127.5, 127.7, 128.4, 128.9, 129.3, 129.5, 131.5, 133.9, 137.4, 152.5 
and 155.3; HRMS (EI) mlz 491.10739 (Mt, C26H22CIN303 requires 491.10704; Anal. 
Calc for C26H22CIN303. 0.75 H20; C, 61.8%; H, 4.4%; N, 8.3%, S, 6.3%, Found C, 
61.5%; H, 4.7%; N, 7.9%; S, 6.6%. 
Naphthalne-2-sulfonic acid [3-(6' -chloro-2' -methoxy-acridin-9'-ylamino )-propyl]-
amide (56). - (0.33 g, 63%), mp 154-157°C(from MeOH); Rf 0.24 (MeOH: CH2Ch, 
1 :9); Vmax (DMSO)/cm-
1 3361 (N-H) and 1319 (S02NH); OR (300 MHz, DMSO-d6) 1.91 
(2H, t, J 6 Hz, ArNHCH2CH2-), 3.85 (2H, t, J 6.6 Hz, ArNH (CH2)2CH2-), 3.87 (3H, s, 
OCH3), 4.05 (2H, br t, ArNHCHr ), 7.08 (H, dd, J2.2 and 9.3 Hz, H3'), 7.26-8.58 (12H, 
m); Oe (75 MHz, DMSO-d6) 30.1, 46.16, 55.6, 55.7, 122.0, 122.6, 123.9, 124.0, 125.0, 
126.2, 126.3, 126.8, 127.1, 127.2, 127.3, 127.4, 127.7, 128.3, 128.5, 128.9, 129.2, 
131.5, 132.6, 133.9, 137.2, 155.0 and 155.2; HRMS (EI) mlz 505.12192 (Mt, 
C27H24CIN303S requires 505.12269; Anal. Calc for C27H24CIN303S.H20; C, 61.9%; H, 
4.6%; N, 8.0%; S, 6.1%, Found: C, 62.2%; H, 4.7%; N, 7.6%; S, 5.8%. 
Naphthalene-2-sulfonic acid [4-(6' -chloro-2' -methoxy-acridin-9'-ylamino )-butyl]-












1 3318 (N-H) and 1464 (S02NH); ()H(300:MHz, DMSO-d6) 1.47 
(2H, quin, 14 x 7.15 Hz, ArNH(CH2)2CHr ), 1.73 (2H, m, ArNHCH2CH2), 2.78 (2H, q, 
13 x 6.5 Hz, ArNH(CH2)3CHr), 3.73 (2H, t, 17.2 Hz, ArNHCH2), 3.90 (3H, s, OCHJ), 
7.29 (H, dd, 12.2 and 9.3 Hz), 7.44 (H, dd, 12.6 and 9.3 Hz), 7.61-7.84 (5H, m), 7.82 
(H, dd, 11.6 and 9.0 Hz), 8.06 (H, d, 18.7 Hz), 8.1 (H, dd, 12.0 and 8.0 Hz), 8.28 (H, 
d, 19.3) and 8.38 (H, d, 11.6 Hz); ()c (75 :MHz, DMSO-d6) 26.5, 27.4, 48.8, 55.6, 101.4, 
113.6, 116.4, 122.1, 122.6, 123.9, 123.9, 124.7, 126.2, 127.2, 127.4, 127.7, 128.2, 
128.4,128.5,129.0,129.2, 131.6,133.9, 134.4,137.4, 146.2, 151.2 and 155.1; HRMS 
(El) mlz 519.14036 (Mt, CZ8Hz6ClN303S requires 519.13834; Anal. Calc for 
CzsH26ClN303S.0.5H20; C, 63.6%; H, 4.9%; N, 8.0%; S, 6.1%, Found C, 63.4%; H, 
5.1%; N, 7.6%; S, 6.3%. 
N aphthalene-2-sulfonic acid [6-(6' -chloro-2' -methoxy-acridin-9' -ylamino )-hexyl]-
amide (58). - (0.085g, 43%), mp 93-95°C (from MeOH); Rf 0.31 (MeOH: CH2Ch, 1 :9); 
Vrnax (DMSO)/cm-1 3318 (N-H) and 1334 (S02NH); ()H (300:MHz, CDCh) 0.95 (2H, m 
ArNH (CHz)4CHr ), 1.37 (4H, m, 2 x CH2), 1.45 (2H, m, ANHCH2CHr ), 1.77 (2H, m, 
ArNH(CH2)CH2-), 3.61 (2H, m, ArNHCHr ), 3.92 (3H, s, OCH3), 7.35 (H, dd,J2.0 and 
9.0 Hz), 7.56 (H, dd, 12.5 and 9.2 Hz), 7.76-7.86 (l0H, m) and 8.37 (H, d, J 9.2 Hz); ()c 
(75:MHz, CDCh) 25.6, 26.0, 26.2, 29.3, 29.4, 31.3, 31.43, 36.4,42.9, 43.0, 50.3, 55.6, 
99.5, 122.3, 124.2, 124.4, 126.6, 127.36, 127.5, 127.9, 128.3 128.7, 129.1, 129.5, 129.6, 
132. 2, 134.7, 136.9, 156.0 and 162.6; HRMS (El) mlz 547.16924 (Mt, C3oH30CIN30 3S 
requires 547.16964; Anal. Calc for C30H30CIN303S.0.5H20; C, 64.7%; H, 5.4%; N, 
7.6%; S, 5.8%, Found C, 65.0%; H, 5.5%; N, 7.2%; S, 6.1 %. 
CI General procedure for preparation of 
ureas 59-62 - Benzyl isocyanate (l.40 
-0 
mmol) was added to a solution of diamine 
(CH:z)nNHCONHCH2 ~ b (1.27 mmol) in dichloromethane (7 
cm3/mmol) and allowed to shake for 4 h at 
20°. The resulting suspension was filtered 











of 61 and 62; the precipitate was chromatographed (Si02, MeOH: CH2Cb, 1 :9) to yield 
the urea. 
Diamines used: 95-95 
I-Benzyl-3- [2-(6'-chloro-2'-methoxy-acridin-9'-ylamino)-ethyl]-urea (59). - (0.33 g, 
96%) as yellow crystals, mp 98-103°C (from MeOH); Rc 0.57 (MeOH: CH2Cb, 1:9); 
Yrnax (CH2Ch)/cm-
1 3730(N-H), 3090 (N-H) and 1598 (C=O); OH (400 MHz, CDCh) 
3.6-3.65 (2H, m, -NHCH2CH2CO-), 3.86 (2H, t, 15.6 Hz, -NHCH2CH2NHCO), 3.98 
(3H, s, OCH3), 4.38 (2H, d, 15.6 Hz, -NHCONHCHr ), 7.09-7.38 (7H, m), 7.48 (1H, d, 
14Hz), 7.90 (lH, d, 19.6 Hz), 7.95 (lH, d, 12.8 Hz) and 8.05 (1H, d, 19.2 Hz); Oe 
(100 MHz, CDCh) 38.9, 39.4, 39.8, 40.1, 43.4, 52.6, 99.6, 112.9, 115.7, 121.8, 122.5, 
123.8, 124.0, 125.6, 126.4, 126.7, 127.8, 133.9, 139.2, 143.0, 148.0, 150.2, 154.9 and 
159.9; HRMS (El) mlz 434.15213 (Mf, C2Ji23ClN40 2requires 434.150953; Anal. Calc 
for C2Ji23ClN402.1.5H20; C, 62.5%; H, 5.0%; N, 12.2%, Found; C, 62.3%; H, 5.3%; N, 
12.6%. 
I-Benzyl-3- [3-(6'-chloro-2'-methoxy-acridin-9'-ylamino)-propyl]-urea (60). - (033 
g, 96%) as yellow crystals, mp 162-166°C (from MeOH); Rr 0.47 (MeOH: CH2Cb, 
1 :9); Y rnax (CH2Ch)/cm-
1 3730(l'I-H), 3090 (C=O) and 1598 (C=O); OH (400 MHz, 
CDCh) 1.80 (2H, m, ArNHCH2CH2CH2NH-), 3.48 (2H, m, ArNHCH2CH2CH2-), 3.73 
(2H, t, 1 6.4 Hz, ArNHCH2(CH2)2NH-), 3.95 (3H, s, OCH3), 4.42 (2H, d, 16Hz, 
ArNH(CH2)3NHCONHCH2Ar), 4.85 (lH, t, 16Hz, -NHCONH-), 5.01 (lH, t, 16.0, -
NHCONH-), 7.21-7.30 (6H, m), 7.35 (IH, dd, 12.4 and 9.2 Hz, H7'), 7.56 (lH, d, 12.8 
Hz, HI'), 7.93 (1H, d, 19.2 Hz, H4'), 8.01 (JH, d, 12.4 Hz, H5') and 8.11 (lH, d,19.6 
Hz, H8 t); oc(100 MHz, CDCh) 31.8, 35.9, 43.5, 45.4,55.1,99.6,117.3,122.8,123.4, 
124.1, 124.6, 125.1, 126.15, 126.8, 126.8, 126.9, 126.95, 127.9, 129.9, 133.9, 139. 6, 
147.85, 150.6, 155.3 and 159.5; HRMS (EI) m/z 448.16687 (Mt, C2sH2sCIN402 
requires 448.16660, AnaL Calc for C2sH2sC1N402.1.5H20; C, 63.1%; H, 5.3%; N, 
11.8%, Found C, 63.5%; H, 5.2%; N, 11.6%. 
I-Benzyl-3- [4-(6'-chloro-2'-methoxy-acridin-9'-ylamino)-butyl] urea (61). - (0.14 g, 












1 3730(N-H), 3090 (CONH) and 1598 (CO); OH (400 MHz, CDCh) 
1.57 (2H, t, J 6.4 Hz, ArNH(CH2)2CH2CH2NHCO-), 1.84 (2H, t, J 9.6 Hz, 
ArNHCH2CHr ), 3.16 (2H, t, J 7.2 Hz, ArNH(CH2)3CH2NH-), 3.84 (2H, t, J 7.2 Hz, 
ArNHCH2(CH2)3NH-), 3.92 (3H, S, OCH3), 4.26 (2H, s, -NHCH2Ar), 7.15-7.25 (6H, 
m), 7.36-7.48 (2H, m), 7.77 (2H, m) and 8.20 (H, d, J 9.2 Hz); Dc (100 MHz, CDCh) 
27.7, 28.0, 39.4, 43.5, 49.4, 55.2, 97.9 100.6, 114.0, 116.9, 123.2, 124.0, 125.4, 126.2, 
126.7,126.8, 126.9, 127.3, 128.2, 130.0, 138.7, 153.1, 140.2, 144.3, 156.2 and 160.0; 
HRMS (El) mlz 462.18569 (Mf, C26H27CIN402 requires 462.182254; Anal. Calc for 
C26H27ClN402.H20; C, 64.g>1o; H, 5.6%; N, 11.7%, Found: C, 64.7%; H, 5.5%; N, 
11.7%. 
N aphthalne-2-sulfonic acid [3-( 6'-chloro-2' -methoxy-acridin-9' -ylamino )-propyl]-
amide (62). - (0.146 g, 73%); mp 115-117°C (from MeOH); Rr 0.61 (MeOH: CH2Cb, 
1:9); Vrnax (CH2Ch)/cm-
1 3730 (N-H), 3090 (N-H) and 1598 (C=O); DH (400 MHz, 
CDCh) 1.40-1.70 (8H, m, 4 x CH2), 3.13 (2H, m, ArNH(CH2)sCH2NHCO-), 3.65 (2H, 
t, J 7.2 Hz, ArNHCHr ), 3.93 (3H, s, OCH3), 4.34 (2H, d, J 5.6 Hz, -NHCH2Ar), 4.77 
(br t, -NHCONH-), 5.14 (br t, -NHCONH-), 7.23-7.38 (8H, m), 7.93-8.01 (3H, m); Dc 
(100 MHz, CDCh) 26.1, 26.2, 29.7, 39.1, 31.4, 39.9, 44.5, 50.0, 55.6, 99.7, 115.3, 
117.6, 124.3, 124.4, 124.6, 127.2, 127.3, 127.4, 128.6, 130.6, 130.9, 135.2, 139.4, 
145.6, 145.9, 147.8, 150.2, 156.0 and 158.5; HRMS (El) 490.21404 (Mf, 
C2SH31CIN402 requires 490.213554; AnaL Calc for C28H31CIN402.3/4H20; C, 66.7%; H, 
6.2%; N, 11.1%, Found C, 66.7%; H, 6.4%; N, 10.9%. 
Cl 
General procedure for preparation of 
amines 63-66 - Diamine (0. 67mmol) was 
added to a solution of benzaldehyde 
-0 (1.01mmol) in methanol (3.5cm
3/mmol). The 
(CH:JnNHCHZ ~ " 
~ // reaction vessel was sealed and then shaken for 
2-3 h at 20°C{96]. The resultant solution was 
treated with Amberlite IRA 400 borohydride 











then shaken at 20°C for an additional 24 h. The polymer beads were removed by 
filtration and washed with several aliquots of methanol. Column chromatography (SiOz, 
CH2Ch: MeOH: Et3N, 8:2:0.1) yielded the desired product. 
Diamines used: 92-95 
N-Benzyl-N'- (6"-chloro-2"-methoxy-acridin-9"-yl)-ethane-l, 2-diamine (63). -
(0.122 g, 61%) as yellow crystals, mp 109-111°C; Rr 0.6 (CHzCh: MeOH: E1JN, 
8:2:0.1) 2; IR (Nujol): Vmax 3311 (N-H) and 1557 (C=C); BH (400 MHz, CDCh) 2.96 
(2H, t, J 5.6 Hz, ArNHCH2CH2NH-), 3.74 (2II, t, J 6.0 Hz, ArNHCHr ), 3.86 (5H, s, 
OCH3 and ArNH(CH2)zNHCH2Ar), 7.21-7.41 (8H, m) and 7.98 ( II, d, J 9.2 Hz, H8"), 
8.05 (II, d, J 2.4 Hz, HI ") and 8.08 (H, d, J 9.2 Hz, H4"); De (50 MHz, CDCh) 29.7, 
48.9, 49.0, 53.4, 55.4, 99.4, 114.7, 116.0, 118.1, 124.2, 124.5, 124.5, 127.3, 128.1, 
128.6,130.7,131.3,134.7,139.9,146.5,146.7,148.4, 150.2 and 155.9; HRMS (El) mlz 
391.14523 (M)', C23H22CIN30 requires 391.14514; Anal. Calc for 
C23H22CIN30.0.5H20; C, 69.0%, H, 5.5%; N, 10.1%, Found: C, 69.4%; H, 5.2%; N, 
10.4%. 
N-Benzyl-N'- (6"-chloro-2"-methoxy-acridin-9"-yl)-propane-l, 3-diamine (64). -
(0.131 g, 70%) as an orange gum; Rr 0.45 (CH2Ch: MeOH: Et3N, 8:2:0.1); IR (Nujol): 
vmaJcm-1 3310.6 (N-H) and 1556.8 (C=C); BH (200 MHz, CDCh) 1.90 (2H, quin, J 4 x 
7.58 Hz, ArNHCH2CHr ), 2.98 (2H, t, J 5.4 Hz, ArNH(CH2hCH2-), 3.79 (2H, s, 
ArNH(CH2)3NHCH2Ar), 3.88 (3H, s, OCH3), 3.93 (2H, t, J 5.8 Hz, ArNHCH2-), 7.18 
(H, dd, J 2.2 and 11.4 Hz), 7.27-7.4 (7H, m), 7.93-8.02 (3II, m); Be(50 MHz, CDCh) 
30.2, 48.9, 51.0, 54.5, 55.3, 100.4, 115.0, 116.9, 123.5, 124.0, 124.7, 126.8, 127.4, 
127,9, 128.1, 128.2, 128.5, 128.7, 131.2, 134.6, 139.5, 146.8, 148.6, 150.5 and 155.3; 
Calc for C2,J!24CIN30; mlz 405.16079. Found HRMS (El) 405.16214 (Mt. 
N-Benzyl-N'- (6"-chloro-2"-methoxy-acridin-9"-yl)-butane-l, 4-diamine (65). -
(0.119 g, 60%) as an orange oil/gum; Rr0.48 (8:2:0.1 CH2Ch: MeOH: Et3N, 0.48); IR 
(Nujol): vmaJcm-1 3312 (N-H) and 1557(C=C); DH (200 MHz, CDC h) 1.65 (2H, q, J 3 x 
7.12 Hz, ArNHCH2CH2), 1.82 (2H, m, ArNH(CH2)2CHr), 2.69 (2H, t, J 6.8 Hz, 
ArNHCH2(CHz)J), 3.77 (2H, s, ArNH(CH2)4NHCH2Ar), 3.91 (3H, s, OCH3), 7.20-
7.43(8H, m), 7.96-8.1 (3H, m); Be (50 MHz, CDCh) 27.5, 29.4, 48.6, 49.2, 50.6, 54.0, 











l34.7, 140.1, 146.8, 148.4, 149.9 and 155.8; Calc for C25H26CIN30; mlz 419.17644. 
Found HRMS (El) mlz 419.17652 (Mt 
N-Benzyl-N'- (6"-chloro-2"-methoxy-acridin-9"-yl)-hexane-l, 6-diamine (66). -
(0.0951 g, 48%) as a yellow-orange oil/gum, Rf 0.49 (CH2Ch: MeOH: Et3N, 8:2:0.1); 
lR (Nujol): Vmax 3312 (N-H) and 1557 (C=C); DH (200 MHz, CDCh) 1.25-1.77 (8H, m, 
4 x CH2), 2.59 (2H, m, ArNH(CH2)5CHr ), 3.67 (2H, t, J7.2 Hz, ArNHCHr ), 3.75 (2H, 
d, J 3 Hz, ArNH(CH2)6NHCH2Ar), 3.94 (3H, s, OCH3), 7.18-7.44 (8H, m), 7.96-8.1 
(3H, m); Dc (50 MHz, CDCh) 26.8, 27.0, 30.0, 31.7, 49.4, 54.1, 55.5, 99.2, 115.9, 
117.9, 123.9, 124.0, 124.4, 124.5, 124.6, 126.8, 126.9, 128.1, 128.2, 128.4, l31.5, 
l34.8, 140.4, 146.7, 148.3, 149.7 and 156.0; Calc for C27H30CIN30; mlz 447.20774. 
Found HRMS (El) mlz 447.20749 (Mt 
Cl 6, 9 Dichloro-acridin-2-o1 (97). 
Method (a) 
a 
Pyridine hydrochloride (2.1 g. 18 mmol) and 6, 9-
dichloro-2-methoxyacridine (1 g, 3.60 mmol) were heated at 210°C for 40 min!79]. The 
reaction mixture was allowed to cool to room temperature and then dissolved in ethyl 
acetate and diluted with water. The organic material was extracted with the ethyl 
acetate. (4 x 70 cm3). The combined organic extracts were then washed with aqueous 
sodium chloride solution (1M, 75cm3), dried over anhydrous sodium sulfate, filtered 
and concentrated. This yielded the alcohol 98 (0.24 g, 25 %) as lime green crystals; mp 
142-145°C (from MeOH); Rf 0.48 (MeOH: CH2Ch, 1:19); IR (MeOH): vmax/cm-
1 3618 
(OH), 3029 (C=C), 1642 (C=C) and 1297 (OB); DH (300 MHz, DMSO-c1;) 7.18 (H, dd, 
J 2.0 and 8.4 Hz, H3), 7.31 (H, dd, J 3.0 and 9.0 Hz, H7), 7.45 (H, d, J 9 Hz, H8), 7.52 
(H, d, J 2.0 Hz, HI), 7.73 (H, d, J 3 Hz, H5) and 8.29 (H, d, J 8.7 Hz, H4); DH (75 MHz, 
DMSO-d6) 101.2, 110.5, 117.6, 120.3, 122.4, 125.5, 130.1 l38.6, 139.9,142.8, 143.0, 
148.7 and 154.17; Anal. Calc for C13H7ChNO; C, 59.1%; H, 2.7%; N, 5.3%; mlz 












Boron tribromide (1.5 cm3, 1.53 mmol) is slowly added to a solution of 6, 9dichloro-2-
methoxyacridine(0.15 g, 0.51 mmol) and dichloromethane (4cm3) previously cooled to-
89°C (dry ice/propan-2-01 bath)[971. The mixture is stirred for 1 h, the cold bath is then 
removed and stirring continued at room temperature for 18 h. The mixture is poured 
into ice-water (12 cm3) and stirred for 1 h resulting in the formation of a yellow 
precipitate. The mixture was filtered and the precipitate dried in vacuo affording the 
alcohol (0.27mg, 20%); 
OH 
6-Chloro-9- (4'- diethylamino - l' - methyl -
butylamino) - acridin - 2 - 01 (98). - Boron 
tribromide (6.3 cm3, 6.25 mmol) is slowly added 
to a solution of quinacrine (0.5 g, 1.25 mmol) 
CI and dichloromethane (12 cm3) previously cooled 
to-89°C (dry ice/propan-2-01 bath)[971. The mixture is stirred for 1 h, the cold bath is 
then removed and stirring continued at room temperature for 18 h. The mixture is 
poured into ice-water (18 cm3) and stirred for 1 h resulting in the formation of a yellow 
precipitate. The mixture was filtered and the precipitate dried in vacuo affording the 
alcohol 152 (0.35 g, 70%); as yellow crystals; mp 270-272°C (from CH2Ch); Rr 0.28 
CNRtOH: MeOH, 1 :4); IR (CHCh): vrnaxlcm·
1 3562 (OH), 3256 (N-H), 3031 (C=C) and 
1535 C=C); CH (300 MHz, CDCh) 097 (6H, t, J 6.9 Hz, -N(CH2CH3)2), 1.02 (3H, d, J 
6.0 Hz, ArNHCHCH3), l.54 (4H, m, 2 x CH2), 2.34 (2H, br t, J 5.1 Hz -CH(CH2)2CH2), 
2.51 (4H, m, 2 x CH2), 3.92 (H, q,J6 Hz, CH), 7.24 (H, dd,J 1.8 and 9.3 Hz, H3'), 7.35 
(H, d, J2.1 Hz, H5'), 7.42 (H, dd, J2.1 and 9.3 Hz, H7'), 7.91 (H, d, J9.3 Hz, H4'), 7.99 
(H, d, J 9.3 Hz, H8') and 8.08 (H, d, J l.8 Hz, HI'); CH (75 MHz, CDCh) 10.7 (2 x 
CH3), 22.0,23.4,30.8,36.4,46.4,52.6,55.4,103.0, 116.7, 120.0, 124.2, 124.7, 126.1, 
127.3, 130.5, 134.8, 145.4, 147.3, 149.1 and 155.0; Anal. Calc for C22H28CIN30; C, 
68.5%; H, 7.3%; N, 10.9%; M 385.1921. Found C, 68.3%; H, 7.3%; N, 10.8%; ~ 385 
(~, 8%),311 (3),271 (2), 140 (4), 126 (22), 112 (7), 99 (9), 91 (14), 86 (100),72 (3), 














General procedure for preparation of ethers 70-
73 - The alcohol 98 (0.17 mmol) and alkyl bromide 
(0.14 mmol) were added to a reaction vessel 
containing 1, 5, 7-triazabicyclo [4.4.0] dec-5-ene 
(PTBD) resin (0.35mmol) in acetonitrile (S.4 
cm3/mmol) as solvent[831. The reaction mixture was shaken vigorously at 24°C for 24 h. 
The polymer beads were removed by filtration and washed with several aliquots of 
methano1. The filtrate was concentrated under reduced pressure yielding the desired 
ether. 
N4_ (6'-Chloro-2'-ethoxy-acridin-9'-yl)-NI, N1-diethyl-pentane-l, 4-diamine (70). -
(0,056 g, 78%) as a brown gum; Rf 0.42 CNIi40H: MeOH, 1:4); IR (MeOH): vrnaJcm-1 
3518 (N-H)' 3031 (C=C), 1559 (C=C) and 1297 (C-O-C); ()H (400 MHz, CDCh) 0.9 
(6H, t,J7.2 Hz, -N (CH2CH3)2), 1.19 (3H, d,J6.8 Hz, ArNHCHCH3), 1.45 (3H, t,J6.S 
Hz, ArOCH2CH3), 1.57 (4H, m, 2 x CH2), 2.31 (2H, t, J7.6 Hz, -CH(CH2)2CHr ), 2.39 
(4H, q, J 5.4 Hz, -N(CH2CH3)2), 3.95 (H, br m, CH), 4.11 (2H, q, J 6.9 Hz, 
ArOCH2CH3), 7.15 (H, d, J 2.8 Hz, H5"), 7.24 (H, dd, J 2.0 and 9.2 Hz, H3'), 7.35 (R, 
d, J2.8 and 9.2 Hz, H7'), 7.92 (H, d, J9.2 Hz, H4'), 7.93 (H, d, J9.2 Hz, H8') and 8.01 
(H, d, J 2 Hz, HI'); ()H (100 MHz, CDCh) 11.5 (2 x CH3), 14.74, 22.21, 23.90, 29.8, 
36.93,46.81, 52.76, 55.91, 63.82, 100.14, 117.8, 119.9, 123.89, 124.86, 124.92, 128.39, 
131.54, 134.7, 146.8, 148.2, 149.5 and 158.00; Anal Calc for C2Ji32CIN30; M 
413.2234; Found M+ 413 (M+, 11%),384(2), (11) and 86 (100). 
N4_ (6'-Chloro-2'-propoxy-acridin-9'-yl}-NI, N1-diethyl-pentane-l, 4-diamine (71). -
(0.082 g, 74%) as a brown gum; Rr 0.39 (NH40H: MeOH, 1 :4); IR (MeOH): vrnaxlcm- l 
3518 (N-H), 3031 (C=C), 1559 (C=C) and 1297 (C-O-C); ()H (300 MHz, CDCh) 0.96 
(6H, t, J 7.2 Hz, -N (CH2CH3) 2), 1.13 (3H, t, J7.2 Hz, ArO(CH2)2CH3), 1.45 (3H, d, J 
6.3 Hz, ArNHCHCH3), 1.57 (4H, m, 2 x CH2), 2.39 (2H, t, J 7.6 Hz, -CH(CH2)2CHr ), 
2.47 (4H, m, -N(CH2CH3)2), 4.07 (2H, t, J 6.3 Hz, ArOCH2CH3), 4.22 (H, br m, CH), 











d, 19.3 Hz) and 8.09 (H, d, 12.1 Hz); OH (100 MHz, CDCh) 10.6, 11.4, 22.2, 22.6, 
23.9,36.9,46.85,51.8,52.8,55.9,63.7,69.86,100.1, 117.2, 119.5, 124.0, 124.9, 128.4, 
131.5, 131.6, 134.7, 146.9, 148.7, 149.2 and 155.7; Anal. Calc for C2sH34ClN30; mlz 
427.23904. Found HRMS (El) mlz 427.24015 (Mf .. 
N4_ (21-butoxy-6'-chloro-acridin-9'-yI)-N\ N1-diethyI-pentane-l, 4-diamine (72). -
(0.09 g, 74%) as a brown gum; Rr 0.43 ~OH: MeOH, 1:4); IR (MeOH): vmaJcm-1 
3518 (N-H), 3031 (C=C), 1559 (C=C) and 1297 (C-O-C); OH (400 MHz, CDCh) 0.86 
(6H, t, 17.2 Hz, -N (CH2CH3) 2), 0.93 (3H, t, 17.2 Hz, ArO(CH2)3CH3), 1.17 (3H, d,1 
6.4 Hz, ArNHCHCH3), 1.57 (6H, m, 3 x CH2), 1.78 (2H, m, ArO(CH2hCH2CH3), 2.38 
(2H, t, 17.6 Hz, -CH(CH2)2CHr ), 2.41 (4H, m, Hz, -N(CH2CH3)2), 3.98 (H, br m, CH), 
407 (2H, t, 16.3 Hz, ArOCH2CH3), 7.15 (H, d, 12.8 Hz, H5 f), 7.26-7.35 (2H, m), 7.38 
(H, dd, 12.58 and 9.4 Hz), 7.98 (H, d, 19.3 Hz) and 8.01 (H, d, 12.1 Hz); OH (100 
MHz, CDCh) 11.7,11.8,14.1,19.6,22.5,24.2,31.5,37.2,47.1,50.9, 53.0, 56.2,68.3, 
100.3,117.6,119.7,124.1,125.2,128.6,131.7,134.9, 146.9, 147.1, 148.4, 149.4 and 
156.0; Anal. Calc for C26H36ClN30; mlz 44l.25469. Found MS (FAB) mlz 441.3 
(M+1t 
N4• (6'-Chloro-2'-pentyloxy-acridin-9'-yI)-N\ N1.diethyl-pentane-l, 4-diamine (73). 
- (0.05 g, 45%) as a brown gum; Rf 0.44 (N&OH: MeOH, 1:4); IR (MeOH): vrnaJcm-1 
3518 (N-H) , 3031 (C=C), 1559 (C=C) and 1297 (C-O-C); OH (300 MHz, CDCh) 0.96 
(9H, superimposed t + t, -N (CH2CH3) 2 + ArO(CH2)4CH3), 1.26 (3H, d, 1 6.0 Hz, 
ArNHCHCH3) , 1.42 (8H, m, 4 x CH2), 1.83 (2H, m, ArO(CH2)2CH2CH3), 2.41 (6H, m, 
-CH(CH2)2CH2- + -N(CH2CH3)2), 4.01 (H, br m, CH), 4.10 (2H, t, 1 6.3 Hz, 
ArOCH2CH3) , 7.15 (H, d, 12.6 Hz, H5'), 7.26-7.35 (2H, m), 7.38 (H, dd, 12.3 and 9.3 
Hz), 7.98 (H, d, 19.3 Hz) and 8.01 (H, d, 1 1.9 Hz); OH (100 MHz, CDCh) 11.5 (2 x 
CH3), 14.1,22.3,22.5,24.0,28.3,28.9,36.9,46.8,50.8, 52.8,55.9,68.4,100.1,117.3, 
119.5,123.9,124.9, 125.0, 128.4, 131.5, 134.7, 147.8, 148.2, 149.2 and 155.8; Calc for 













N' - (2-Allyloxy-6-chloro-acrdin-9-y)-N1, N1_ 
diethyl-pentane-1, 4-diamine (99). - Allyl Bromide 
(0.035cm3, 0.41mmol) was added to a solution of 
alcohol 97 (0.1 g, 0.38 mmol) in N, N' 
Dimethylformamide (4.76 cm3), followed by 
potassium carbonate (0.52 g, 3.8 mmol). The reaction mixture was stirred at 18°C for 20 
h. The reaction mixture was then diluted with water (20 cm3) and the organic product 
extracted with ethyl acetate (3 x 30cm3). The combined organic extracts were washed 
with brine, dried over anhydrous sodium sulfate, filtered and concentrated to yield the 
ether. This was carried forward to the next step without purification. Ether 100 (0.04 g, 
0.11 mmol) was reacted with amine 101 (0.09 g, 0.36 mmol) and stirred under nitrogen 
in the presence of N-methyl-2-pyrrolidinone (0.78 cm3i 981, triethylamine (0.023 cm3, 
0.17 mmol) and potassium carbonate (0.005 g, 0.34 mmol) at 135-145°C. The reaction 
is stopped and cooled to room temperature. The product was washed with 
dichloromethane and brine before being separated. The organic extracts were dried over 
anhydrous sodium sulfate, filtered and concentrated yielding the desired ether 99 
(0.029g, 61%) as a yellow gum; Rf (5% MeOH: CH2Ch) 0.74;IR (MeOH): vrnaxlcm-1; 
BH (200MHz, CDCh) 0.85 (6H, superimposed t+t, 2 x CH3), 1.26 (3H, d, J 8 Hz, 
ArNHCHCH3), 1.57 (4H, m, 2 x CH2), 2.36 (6H, m, 3 x -CH2N(CH2CH3)2), 4.67 (2H, 
dd, J 1.3 and 5.3 Hz, ArOCH2-), 5.32 (H, d, J 10.7 Hz, ArOCH2CH-), 5.47 (H, dd, J 1.6 
and 18.8 Hz, ArOCH2CH-), 5.95-6.02 (2H, m, ArOCH2CHCH2), 7.16 (2H, dd, J 1.6 
and 8.4 Hz), 7.31 (2H, m), 7.88 (H, d, J3.6 Hz) and 8.42 (H, d, J 8.8 Hz); Be (50 MHz, 
CDCh) 13.73, 21.60, 25.22, 30.85" 49.45, 69.30, 108.01, 114.65, 116.99, 117.77, 
118.04, 121.86, 125.08, 129.43, 13l.01, 134.97, 148.12, 148.56 and 156.83; Calc for 
C25H32CIN30 425.22339; HRMS (E1) mlz 125.22121 (Mr. 
4-0xo-pentanoic acid diethylamide (104). - Levulinic acid (1.1 g, 9.47 mmo!) 102 
-?
o I was dissolved in dry CH2Ch (5.5 cm3) under nitrogen and the 
N 3 
'-- solution cooled to O°e. Oxalyl chloride (1.24 em , 14.21 mmol) 
was added to the mixture which was stirred at O°C for 3 h. The 
o solvent was removed under reduced pressure and the residue 











diethylamine (1.96cm3, 1.9mmol) in CH2Ch (2 cm
3
) was slowly added to the solution 
via a dropping funnel. The mixture was then allowed to warm to 20°C and was stirred 
for 1 h. Column chromatography (Si02, MeOH: CH2Ch, 1:19) yielded the desired 
compound 104 (1.1 g, 65%) as a pale yellow oil. Rf 0.55 (MeOH: CH2Ch, 1:19); IR 
(CHCb) vmaxlcm-
1 1710 (C==O of amide), 1624 (C=O of ketone); OH (400 MHz, CDCb) 
1.09 (3H, t, J 7.1 Hz, CONHCH3), 1.19 (3H, t, J 7.1 Hz, CONCH2CH3), 2.20 (3H, s, 
CH3COC-), 2.58 (2H, 1, J 6.4 Hz, -CH2CH2CON), 2.78 (2H, t, J 6.8 Hz, -
CH2CH2CON), 3.34 (4H, m, CO (CH2CH3h), oe (100MHz, CDCh) 13.0, 14.1,27.0, 
30.1, 38.2, 40.3, 41.8, 170.6, 208.0; Calc for C9H17N02; mlz 171.1259. Found HRMS 
(El) mlz 171.1245 (Mt 
4-Hydroxyimino-pentanoic acid diethylamide (103). 
-?-o ;- Method (a): The ketone 104 (1.1 g, 6.2 mmol) and '-- hydroxylamine hydrochloride (0.69 g, 9.9 mmol) were dissolved ~N in ethanol (30 cm3i 991 . Sodium hydroxide (0.79 g, 20.32 mmol) 
Hd in water (5.1 cm3) was added dropwise to the ethanol solution 
with stirring. The solution was refluxed with stirring for 2 h and quenched with water 
(30 cm3). The resulting solution was neutralized by treatment with CO2 gas and 
extracted with dichloromethane (2 x 30 cm3). The combined organic fractions were 
dried over sodium sulfate, filtered and concentrated. The compound was purified by 
column chromatography (Si02, MeOH: CH2Ch, 1:19) to give the oxime 103 (0.98 g, 
86%) as clear oil. 
Rf 0.50 (MeOH: CH2Ch, 1: 19); IR (CHCh) vmax/cm-
1 3665, 3589, 3294 (OH), 1728 
(C=O); OH (400 MHz, CDCb) 1.24 (6H, t, J 6.8 Hz, -N(CH2CH3)2), l.86 (3H, S, CH3-
C=N-), 2.52 (2H, m, -CH2-CON-), 4.13 (4H, quartet, J 7.2 Hz, -N(CH2CH3)2); Oe 
(100MHz, CDCb) 13.8, 14.1, 24.2, 30.9, 44.7, 156.5, 172.7; HRMS (El) mlz 186.1373 
(Mt (C9H18N202 requires 186.1368). 
Method (b): 
Pyridine (0.26 cm3, 2.9 mmol) and hydroxylamine hydrochloride (0.22 g, 3.19 mmol) 











resulting solution was refluxed for 30 min with stirring. On completion of the reaction, 
the solvent was removed under reduced pressure. The residue was diluted with water 
and the organic product extracted with ethyl acetate (2 x 30 cm3), dried over anhydrous 
sodium sulfate, filtered and concentrated to give the oxime 103 (0.29 g, 59%) as a clear 
oil. 
Nt, Nt_ Diethyl-pentane-1, 4-diamine (101). - Lithium 
aluminium hydride (0.31 g, 8.06 mmol) was suspended in dry 
tetrahydrofuran (5cm3) under nitrogen and cooled to 0°C[99]. 
Oxime 103 was dissolved in dry tetrahydrofuran (3 cm3) and this 
was slowly added to the LAH slurry. The solution was allowed to warm to ambient 
temperature and then heated under reflux for 6 h. After cooling; the reaction was 
quenched with excess diethyl ether. The solution was transferred to a separating funnel 
and washed with brine (20 em3). The organic layer was dried over potassium carbonate 
and concentrated under reduced pressure to afford the amine 101 (0.28 g, 67%) as pale 
yellow oil; Rf 0.60 ~OH: MeOH, 1:19); IR (CHCh) vmax!cm-l 3406 (NH stretch); 
OH (300 :MHz, CDCh) 1.00 (9H, m, -CHrCH- and -N(CH2CH3)2), 1.28 (2H, quin, J 4 x 
7.7 Hz, -C-CH2-C-), 1.44 (2H, q, J 3 x 7.1 Hz, -CH-CHr) 1.60 (2H, br s, NH2-
disappears in D20), 2.37 (2H, t, J 7.3 Hz, -CH2N(CH2CH3h), 2.49 (4H, q, J 3 x 7.1 Hz, 
-N(CH2CH3)2), 2.86 (H, sextet, J 6.2 Hz, -CH-); Oc (75 :MHz, CDCh) 11.5, 23.9, 30.7, 





2-( 6' -Chloro-2' -methoxy-acridin-9'-ylamino)-
ethanol (105).-
A mixture of 6,9-dichloro-2-methoxyacridine (1.5 g, 
5.4 mmo!), ethanolamine (l0.4 cm3, 173 mmol) and 
phenol (4.2 g) was heated at 90°C for 4 h. The resulting yellow mixture was cooled 
before 210 cm3 of water was added yielding a yellow precipitate. This was isolated by 











g, 80%) as yellow crystals, mp 190-193°C (from MeOH); IR (MeOH): vmaxlcm-
13563 
(N-H), 3548 (OH), 3050 (C=C), 1620 (C=N) and 1390 (OH); OH (300 MHz, DMSO-d6); 
3.75 (4H, dd, 14.8 and 24.9 Hz, 2 x CH2), 3.93 (3H, s, OCH3), 6.71 (H, br s, ArNH), 
7.37 (2H, m, H3' and HT), 7.66 (H, d, 12.7 Hz, H5'), 7.86 (2H, m, HI' and H4') and 
8.39 (H, d, 19.0 Hz, H8'); oe(75 MHz, DMSO-d6) 51.8,55.6,60.7, 100.7, 114.9, 117.3, 
122.8, 124.2, 126.3, 127.2, 130.8, 133.4, 146.2, 148.1, 150.6 and 155.1; Anal. Calc for 
C16H1SCIN202; C, 63.5%; H, 5.0%; N, 9.3%; mlz 302.08220. Found C, 63.0%; H 4.8%, 






Diethylazodicarboxylate (0.26 cm3, 1.65 
mmol) was added dropwise to a stirred 
solution of triphenylphosphine (0.43 g, 
1.65 mmol) in dichloromethane (7 cm3) at O°e. After 20 min, a solution of alcohol 67 
(0.5 g, 1.65 mmol) and 4-hydroxy-2-methoxy-benzaldehyde (0.25g, 1.65mmol) in 
anhydrous dichloromethane (7 cm3) was added slowly to the reaction mixture which 
was stirred at O°C for 1 h. Thereafter, the solution was allowed to warm to room 
temperature and stirred for a further 23 h. Solvent was removed under reduced pressure 
and the residue chromatographed (Si02, MeOH: CH2Ch. 1: 19) to afford the ether 68 
(0.36 g, 58%) as yellow crystalline material; mp 80-82°C (from EtOAC/pet ether); Rr 
0.44 (MeOH: CH2Ch, 1:19); IR (MeOH): Vmax!cm-1 3517 (N-H), 3059 (C==C), 1712 
(C=O), 1559 (C=C) and 1297 (C-O-C-); OR (300 MHz, CDCb) 3.75 (2H, t, 19.0 Hz, 
ArNHCH2CH2-), 3.86 (6H, d, 14.8 Hz, 2 x OCH3), 4.27 (2H, m, ArNHCH2CH2) 6.39 
(H, d, 12.4 Hz), 6.54 (H, dd, 11.8 and 8.7 Hz), 7.25-7.28 (2H, m), 7.33 (H, dd,1 1.8 
and 7.2 Hz), 7.40 (H, dd, 12.4 and 9.3 Hz), 7.80 (H, d, J8.7 Hz), 8.00 (H, d, J9.3 Hz), 
8.10 (H, d, 19.0 Hz) and 10.29 (H, s, COll); OR (75 MHz, CDCh) 50.8, 55.7, 63.04, 
67.7, 98.3, 98.9, 99.4, 99.92, 106.4, 107.3, 110.4, 124.2, 124.2, 125.3, 125.5, 127.7, 
130.1, 130.9, 140.8, 141.0, 157.6, 159.5, 163.2 and 188.23; Anal. Calc for 
C2Ji21 ClN204,C, 64.0%; H, 4.8%; N, 6.4%; mlz436.1189 Found C, 64.3%; H, 5.1%; N 












9'-ylamino )-ethoxy ]-2-methoxyphenyl} 
ethan one (69).-
Diethylazodicarboxylate (0.26 cm3, 1.65 
I mmo!) was added dropwise to a stirred 
solution of triphenylphosphine (0.43 g, 
1.65 mmol) in dichloromethane (7 cm3) at O°c. After 20 min, a solution of alcohol 67 
(0.5 g, 1.65 mmol) and 4-Hydroxyacetophenone (0.22 g, 1.65 mmol) in anhydrous 
dichloromethane (7 cm3) was added slowly to the reaction mixture which was stirred at 
O°C for 1 h. Thereafter, the solution was allowed to warm to room temperature and 
stirred for a further 23 h. Solvent was removed under reduced pressure and the residue 
chromatographed (Si02, MeOH: CH2Ch, 1:19) to afford the ether 69 (0.18 g, 26%) as a 
yellow gum; Rf0.35 (MeOH: CH2Ch, 1:19); IR (MeOH): vmaJcm-
1 3517 (N-H), 3059 
(C=C), 1712 (C=O), 1559 (C=C) and 1297 (C-O-C-); DH (300 MHz, CDCh) 2.55 (3H, 
s, CH3), 4.05 (2H, t, 15.1 Hz, ArNHCH2CH2) , 4.12 (2H, t, 14.8 Hz, ArNHCH2CH2), 
6.92 (H, d, 19 Hz), 7.25-7.69 (5H, m), 7.92 (H, d, 19.0 Hz), 7.99 (H, d, 19.3 Hz) and 
8.6-8.09 (2H, m); DH (75 MHz, CDCh) 14.4,26.3, 55.4, 67.4, 98.7, 114.2, 124.1, 125.2, 
125.4, 127.7, 127.9, 128.4, 128.6, 130.7, 131.1, 131.7, 131.9, 131.98, 132.00, 132.1, 
133.1, 156.7, 162.1 and 196.6; Anal. Calc for C2~21CIN203; m/z 420.12407; Found 











6.3 PROCEDURES FOR QUINOLINE ANALOGUES 
General procedure for preparation of quinoline 
HN -(CHZ)n-NHZ 
amines 107-110 - A mixture of 4,7-dichloroquinoline (2 
g, 10.10 mmol) and the diaminoalkane (45.45 mmol) was 
CI heated at 80°C for 1 h with stirring [100]. Thereafter, at 
13S-14SoC for 3 h. Sodium hydroxide (1M, SO cm3) was added and the organic product 
extracted with ethyl acetate (4 x 250 cm3). The combined organic extracts were washed 
with water, dried over anhydrous sodium sulfate and concentrated to yield the amine. 
Diaminoalkanes used: 1, 3 diaminopropane, 1, 4 diaminobutane, 1, 6 diaminohexane 
and 1, 3 diaminoethane 
N l . (7'-Chloro-quinolin-4'-yl)-propane-l, 3-diamine (107). - (1.8 g, 91%) as white 
crystals, mp 124-127°C (from MeOH), Rf 0.34 ~OH: MeOH, 1:19); IR (Nujol): 
vmax!cm- I 3S18 (NIh), 3437 (NH2), 3029 (C=C), 1612 (NH2), 1582 (C=C and C=N); OH 
(300MHz, CDCh) 1.87 (2H, m, ArNHCH2CH2-), 3.02 (2H, t, J 5.7 Hz, ArNH 
(CH2)2CH2NH2), 3.39 (2H, m, ArNHCH2 -), 6.33 (H, d, J5.4 Hz, H3'), 7.27(H, d, J2.4 
and 9.0 Hz, H5'), 7.69(H, d, J 9.0 Hz, H6'), 7.91 (H, d, J2.4 Hz, H8'), 8.48 (H, d, J 5.4 
Hz, H2'); be (CDCh) 30.1, 41.4, 43.6, 98.3, 117.5, 121.9, 124.9, 128.6, l34.7, 149.2, 
150.4 and 152.1; Anal. Calc for C12H14CIN3; 61.15%; H, 6.0%; N, 17.8%; mlz 
235.08763. Found C, 61.1%; H, 5.9%; N, 17.9%; HRMS (EI) mlz 235.08918 (Mt. 
N l _ (7'-Chloro-quinolin-4'-yl)-butane-l, 4-diamine (l08). - (1.76 g, 89%) as a white 
powder; mp 45-48°C (from MeOH); RrO.88 (MeOH: CH2Ch, 1:9); IR (Nujol): vmax/cm-
1 
3518 (NH2), 3437 (NH2), 3029 (C=C), 1612 (NH2), 1582 (C=C and C=N); OH (300 
MHz, CDCh) 1.62 (2H, m, ArNH(CH2)zCH2-), 1.89 (2H, m, ArNHCH2CHr ), 3.04 
(2H, t, J 6 Hz, ArNH(CH2)3CH2-), 3.41 (2H, m, ArNHCHr ), 6.32 (H d, J 5.7 Hz, H3'), 
7.31 (H dd, J2.4 and 9.0 Hz, H6'), 7.71 (H d, J9.0 Hz, H5'), 7.92 (H, d, J2.4 Hz, H8') 
and 8.49 (H, d, J 5.7 Hz, H2'); oe (75 MHz, CDCb) 30.0 (2 x CH2), 41.4, 43.6, 98.3, 











C, 62.5%; H, 6.4%; N, 16.8%; mlz 249.10327. Found C, 62.1%; H, 6.5%; N, 16.2%; 
HRMS (FAB) mlz 250.1 (M+l)+. 
N1_ (7'-Chloro-quinolin-4'-yl)-hexane-1, 6-diamine (109). - Column chromatography 
(Si02-NI140H: MeOH, 1:19) yielded the amine (1.73 g, 87%) as white crystals; mp 
135-137°C (from MeOH) (lit[lOlJ 135.8-136.8); Rf 0.88 (NI140H: MeOH, 1:9); IR 
(Nujol): Vmax/cm-1 3518 (NH2), 3437 (NH2), 3029 (C=C), 1612 (NH2), 15825 (C=C and 
C=N); OH (400 MHz, CD30D) 1.51 (6H, m, 3 x CH2), 1.77 (2H, m, ArNHCH2CH2-), 
2.67 (2H, t, J7.2 Hz, ArNH(CH2)sCHr ), 3.36 (2H, t, J7.2 Hz, ArNHCHr ), 6.50 (H, d, 
J 5.8 Hz, H3'), 7.38 (H, d, J 2,4 and 9.0 Hz, H6,), 7.77 (H, d, J 2,4 Hz, H8'), 8.01 (H, d, 
J 9.0 Hz, H5') and 8.34 (H d, J 5.8 Hz, H2'); Oe (l00 MHz, CD30D) 26.5, 26.7, 28.2, 
31.8,41.0,42.7,98,4,117.6,119.2, 123.1, 124.7, 126.4, 135.1, 148.6 and 151.3; Anal. 
Calc for ClsH20ClN3; C, 64.9%; H, 7.2%; N, 15.1%; mlz 277.13457. Found C, 64.7%; 
H, 7.5%; N, 15.6%; HRMS (FAB) mlz 278.2 (M+lt 
N1_ (7'-chloro-quinolin-4'-yl)-ethane-1, 2-diamine (110). - (1.71, 77%) as white 
crystals, mp 137-139°C (from MeOH)(lit[lOll; 137-139°C) Rf 0.22 (MeOH-CH2Cb, 
1:9); IR (Nujol): vrnax!cm-1 3518 (NH2), 3437 (NH2), 3029 (C=C), 1612 (NH2), 1581.5 
(C=C and C=N); OH (400 NIHz, CD30D) 2.81 (2H, t, J 6.4 Hz, ArNHCH2CH2NH2), 
3.27 (2H, t, J 6,4 Hz, ArNHCH2CH2NH2), 6.36 (H, d, J 5.6 Hz, H3'), 7.19 (H, dd, J 2,4 
and 9.0 Hz, H6'), 7.57 (H, d, J 2.4 Hz, H8'), 7.91 (II, d, J 9.0, H5') and 8.12 (H, d, J 5.6 
Hz, H2'); Oe (l00 MHz, CD30D) 39.5, 44. 6, 53.6, 98.6, 117. 7, 123.2, 124.9, 126.4, 
135.3,148.5 and 151.3; AnaL Calc for CnH12ClN3; C, 59.6%; H, 5.5%; N, 17.9%; mlz 
221.07198; Found: C, 59.5%; H, 5.2%; N, 17.8%; HRMS (EI) mlz 221.07194 (Mt. 
chloro-q uinolin-4' -ylamino )-hutyl}-
I ~ ~ # amide (77). -
CI Q N
b ~ I To a mixture of 108 (0.98 g, 3.93 mmol) 
and triethylamine (1.1 cm3, 7.86 mmol) in N, N dimethylformamide (7 cm3). -2-
Naphthalenesulfonyl chloride (1.25 g, 5.502 mmol) was added and the reaction mixture 











reaction resulting in the formation of a precipitate. The crude product was 
chromatographed (Si02-MeOH-CH2Ch, 1:9) to yield the sUlfonamide 77 (0.83 g, 84%); 
Rr 0.42 (MeOH: CH2Ch, 1 :9); IR (Nujol): vmaJcm-
1 3687 (N-H), 3646 (N-H), 1524 
(C=C) and 1376 (S=O); OH (400 MHz, CDCh) 1.64 (2H, quin, 14 x 7.4 Hz, CH2), 1.81 
(2H, quin, 1 4 x 7.6 Hz, CH2), 3.02 (2H, t, 1 6.4 Hz, ArNHCHr ), 3.28 (2H, br t, 
ArNH(CH2)JCH2-), 6.25 (H, d, 16.8 Hz, H3'), 6.85 (H br s, ArNH(CH2)~HS02Ar), 
7.16 (II, dd, 12.0 and 8.8 Hz, H6'), 7.51-7.99 (9H, m) and, 8.25 (II, d, 16.4 Hz, H2,); Oe 
(100 MHz, CDCh) 25.3,27.0,40.0,42.8,98.4,122.3,123.0,124.0, 125.7, 126.3,126.8, 
127.5, 127.8, 127.9, 128.3, 128.8, 128.9, 129.2, 129.5, 132.0, 134.8, 149.2 and 151.7 ; 
AnaL Calc for C23H22CIN30 2S; C, 62.8%; H, 5.0%; N, 9.6%; S, 7.3%; mlz 439.11213. 
Found: C, 62.7%; H, 5.4%; N, 9.7%; S, 7.6%; HRMS (EI) mlz439.11317 (Mt. 
Naphthalene-2-sulfonic acid benzyl- [4-(7'-
chloro-quinolin-4'-ylamino)-butyl]-amide (78). -
Benzyl bromide (0.35 cm3, 2.94 mmol) was added 
to a solution of 77 (1.2 g, 2.75 mmol) in N, Nt 
Dimethylformamide (34cm3), followed by 
potassium carbonate (3.80 g, 27.5 mmol). The 
reaction mixture was stirred at 20°C for 24 h, 
thereafter diluted with water and extracted with 
ethyl acetate (3 x 70cm\ The combined organic extracts were washed with brine, dried 
over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The 
crude product was chromatographed (Si02, MeOH: CH2Ch, 1: 19) to give the desired 
product 78 (0.58 g, 48%); m.p. 99-102°C (from EtOAc/pet ether); Rf 0.38 (MeOH: 
CH2Ch, 1:19); IR (Nujol): vrnaxlcm·
1 3377 (N-H), 1519 (C=C) and 1365 (S=O); OH 
(400 MHz, CDCh) 1.47 (2H, m, ArNHCHlCH2h), 1.57 (2H, quin, 1 4 x 7.2 Hz, 
ArNHCH2CH2(CH2)2), 3.11 (2H, q, 13 x 5.6 Hz, ArNH(CH2)2CH2-), 3.20 (2H, t, 17.2 
Hz, ArNH(CH2)3CHr ), 4.33 (2H, s, NHCH2Ph), 5.01 (H, br t, ArNH), 6.22 (II, d, 16.4 
Hz), 7.19-7.24 (4H, m), 7.57-7.98 (lOll, m), 8.36 (H, d,1 1.6 Hz) and 8.44 (II, d, 1 1.6 
Hz); oe (l00 MHz, CDCh) 25.4, 26.1, 42.6, 48.2, 52.9, 98.9, 117.1, 121.1, 121.3, 
122.37, 125.2, 127.7, 127.9, 128.0, 128.4, 128.5, 128.6, 128.7, 128.8, 129.2, 129.5, 











C30H28CIN302S; C, 67.8%; H, 5.3%; N, 7.9%; S, 6.1 %; mlz 530.1; Found C, 67.7%; H, 




To a mixture of 110 (2.0 g, 7.21 mmol) 
and triethylamine (2 cm3, 14.42 mmol) 
in N, N' dimethylformamide (l3cm3) was added 2- naphthalenesulfonyl chloride (2.29 
g, 10.1 mmol) and the reaction mixture was allowed to shake for 18 h[95] at 20°C. Water 
(40 cm3) was then added to quench the reaction resulting in the formation of a 
precipitate. The crude product was chromatographed (Si02, MeOH: CH2Ch, 1 :9) to 
yield the sulfonamide 79 (1.52 g, 72%); m.p. 132-135°C (from EtOAc/pet ether); Rf 
0.36 (MeOH-CH2Ch, 1:9); IR (Nujol): Ymax/cm- I 3687 (N-H), 3646 (N-H), 1581 (C=C) 
and 1153 (S=O); OH (400 MHz, CDCb) 0.82 (2H, m CH2), 1.37 (6H, m, 3 x CH2), 3.00 
(2H, m, CH2), 3.23 (2H, m, CH2), 6.34 (H, d, J 5.4 Hz, H3'), 7.33(H, dd, J, 2 and 8.8 
Hz, H6'), 7.59-7.95 (8H, m), 8.41 (H, d, J 1.2 Hz) and 8.48 (H d, J 5.4 Hz, H2'); Oc (100 
MHz, CDCb) 26.0, 28.6, 29.7, 30.2, 43.0, 51.1, 83.7, 90.5, 99.0, 102.9, 107.6, 110.7, 
115.4, 117.4, 121.0, 122.3, 127.9, 128.4, 128.8, 129.5, 134.8, 138.2, 141.1, 146.3 and 
151.6; Anal. Calc for C2sH26CIN302S; C, 64.2%; H, 5.6%; N, 8.9%; S, 6.9%; mlz 
467.14343. Found: C, 64.4%; H, 5.6%; N, 8.5%; S, 7.2%; HRMS (EI) mlz 467.14205 
(M)+. 
Naphthalene-2-sulfonic acid benzyl- [6-(7'-
chloro-q uinolin-4'-ylamino )-hexyl]-amide 
(80). -
Benzyl bromide (0.40 cm3, 3.33 mmol) was 
added to a solution of79 (1.5 g, 3.11 mmol) in 
N, N' dimethylformamide (39 cm3), followed 
by potassium carbonate (4.30 g, 31.1 mmol). 











24 h. Thereafter; it was diluted with water and extracted with ethyl acetate (3 x 70cm3). 
The combined organic extracts were washed with brine, dried over anhydrous sodium 
sulfate, filtered and concentrated under reduced pressure. The crude product was 
chromatographed (Si02, MeOH: CH2Ch, 1: 19) to give the product SO (0.88 g, 60 %) as 
a yellow oil; Rr 0.19 (MeOH: CH2Ch, 1:19); IR (Nujol); vrnJcm-1 3252 (N-H), 1567 
(C=C) and 1351. (S=O); OH (400 MHz, CD30D) l.17 (4H, m, 2 x CH2), 1.31 (2H, m, 
CH2), 1.50 (2H, m, CH2), 3.17 (4H, m, CH2), 4.38 (2H, s, -NHCH2Ph), 6.39 (H, d, J 5.6 
Hz, H3'), 7.17-7.37 (5H, m), 7.59-8.05 (9H, m), 8.32(H, d, J 5.6 Hz, H2') and 8.4 (H, d, 
J 1.6 Hz); Oc (100 MHz, CDCh) 27.2, 27.4, 29.0. 29.01, 43.8,45.0, 53.2, 99.6, 119.1, 
123.6, 124.3, 125.9 2 x H), 127.5 (2 x H), 128.7, 128.8, 129.0, 129.4, 129.5, 129.5, 
129.9, 130.2, 130.6, 133.7, 136.3, 138.3, 138.4, 149.6, 152.3 and 152.7; Anal. Calc for 
C32H32CIN30 2S; mlz 557.190377. Found MS (FAB) mlz 558.1 (M+lt 
HlCOYOI ~ ~ ~ Naphthalene-2-sulfonic acid [4-(6'-
~ Nb ° ~ methoxy-quinolin-S'-ylamino)-
,,~ 
HN~N/\ pentyl]-amide (74). -
I H ° To a mixture of primaquine (2.45 g, 
9.49 mmol) and triethylamine (2.65 cm3, 18.98 mmol) in N, N' dimethylformamide (16 
cm3) was added 2-naphthalenesulfonyl chloride (3.0g, 13.29 mmol) and the reaction 
mixture was shaken for 18 h at 20°C. Water (48 cm3) was then added to quench the 
reaction resulting in the formation of a precipitate. The crude product was 
chromatographed (Si02, EtOAc: Hex, 1 :2.3) to yield the sulfonamide 74 (2.36 g, 96%) 
as a dark oil; Rr 0.36 (EtOAc: Hex, 1 :2.3); IR (Nujol): vrnaxlcm-1 3388 (N-H) and 1329 
(S=O); OH (400 MHz, CDCb) 1.18 (2H, d, J 5.6 Hz, CH3), l.60 (4H, m, CH2), 2.99 (2H, 
m, CH2), 3.45 (H, br m, CH), 3.85 (3H, s, OCH3), 4.61 (H, t, J 6.0 Hz, NHS02Ar), 
5.89(H, br t, ArNH-), 6.19 (H, d, J 2.0 Hz,), 6.30 (H, d, J 2.4 Hz), 7.24-7.90 (8H, m), 
8.38 (H, d, J 1.6 Hz) and 8.48 (H, dd, J 2.0 and 4.4 Hz); Oc (100 MHz, CDCh) 20.6, 
26.4,33.6,43.3,47.7,55,2,91. 9, 96.9, 12l.8, 122.3, 122.5, 127.5, 127.9, 128.4, 128.7, 
129.2, 129. 5, 129.9, 132.2, 134.8, 135.3, 136.8, 144.3, 144.8 and 159.4; AnaL Calc for 














Benzyl bromide (0.67 cm3, 5.64 mmol) 
was added to a solution of 74 (2. 4g, 5.27 
mmol) in N, N' dimethylformamide (66 
cm\ followed by potassium carbonate (7.30 g, 31.1 mmol). The reaction mixture was 
stirred at 20°C for 24 h. Thereafter, it was diluted with water (100cm3) and extracted 
with ethyl acetate (4 x 100 cm3). The combined organic extracts were washed with 
brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced 
pressure. The crude material obtained was recrystallized from methanol to give the 
desired product 75 (0.88 g, 60%) as beige crystals; mp 152-155°C (from MeOH); Rr 
0.77 (MeOH: CH2Ch, 1:19); IR (Nujol): vmax!cm-
1 3252 (N-H), 1568 (C=C) and 1351. 
(S=O); OH (400 MHz, CDCh) 1.07 (3H, d, J 6.4 Hz, CH3), 1.45 (4H, m, 2 x CH2), 3.17 
(2H, m, CH2), 3.36 (H, br m, CH), 3.86 (3H, s, OCH3), 6.13 (H, d, J2.4 Hz), 6.30 (H, d 
J2.4 Hz), 7.18-7.29 (6H, m), 7.55-7.91 (7H, m), 8.36 (H, d, J 1.6 Hz) and 8.48 (H, dd, J 
1.6 and 4.4 Hz); oc (100 MHz, CDCh) 20.4, 24.6, 33.5, 47.5, 48.0, 51.9, 55.2, 66.0, 
91.7,96.7, 121.5, 12l.8, 122.5, 122.7, 127.4, 127.8, 128.0, 128.4, 128.5, 129.2, 129.4, 
129.5, 130.0, 132.2, 134.7, 136.2, 136.3, 137.0, 142.0, 144.2 145.6 and 159.4; Anal. 
Calc for C32H33N203S; C, 71.2%; H, 6.2%; N, 7.8%; S, 5.9%; mlz 539.2243. Found C, 
71.1%; H, 6.4%; N, 7.6%; S, 5.3%; MS (FAB) mlz 540.4 (M+1t. 
HJCO~~ 4-Chloro-N- [4-(6'-methoxy-quinolin-S'-
I #.& ~C! ylamino)-pentjl]-benzene sulfonamide 
HN N O~N (76). - Aryl SUlfo~YI chlorid~ (7.49 mmol) 
~~/, was added to a mIxture ofpflmaquine (5.35 
mmol) and triethylamine (1.49 cm3, 10.7 
mmol) in N, N' dimethylformamide (9 cm3)[951. The reaction mixture was shaken for 18 
h at 20°C. Water (0.37 cm3/mmol) was added resulting in the formation ofa precipitate 
which was isolated by filtration. Chromatography (Si02, MeOH: CH2Ch, 1 :4) yielded 











(DMSO)/cm-1 3343 (N-H) and1371 (S=O); oH (300 MHz, CDCh) 1.23 (3H, d, J 6.3 Hz, 
CH3), 1.62 (4H, m, CH2), 2.97 (2H,m, CH2), 3.51 (H, br m, CH) 3.88 (3H, s. OCH3), 
4.7 (H, t, J 6. O-NHS02Ar), 5.59 (H, br s, -CH2NHAr), 6.2 (H, d, J2.6 Hz), 6.34(H, d, J 
2.57 Hz), 7.28-7.4(3H, m), 7.74-7.77(2H, m), 7.99(H, dd, J 6.54 and 8.13 Hz) and 8.5 
(H, dd, J2.6 and 4.2); oeC75 MHz, CDCh) 20.6,26.3,33.6, 43.2,47.7, 55.2, 9l.9, 96.9, 
121.7, 12l.9, 128.4, 129.3, 129.9, 134.8, 125.3, 138.6, 139.0, 144.4, 144.8, 144.9 and 
159.4; Anal. Calc for C21H24CIN303S; mlz 433.12269. Found HRMS (El) mlz 
433.12398 (M+). 
II General procedure for preparation of 
HN~-rl-R sulfonamides 81-82 - Amine 107 (2.12 mmol) 
o and triethylamine (4.24 mmol) were mixed in N, 
a 
N' dimethylformamide (1.1 cm3/mmol)[951. Aryl 
sulfonyl chloride (2.97 mmol) was added and the mixture shaken for 18 h at 20°C. 
Water (4.7cm3) was added and the resulting precipitate, which was isolated by filtration. 
Chromatography (Si02, MeOH: CH2Ch, 1 :9) yielded the sulfonamide. 
Aryl sulfonyl chlorides used: 4-Chlorosulfonyl chloride and 2-naphthalenesulfonyl 
chloride 
N aphthalene-2-sulfonic acid [3-(7' -chloro-quinolin-4 t -ylamino )-propyl]-amide (81) 
- (0.36g, 72%) as white crystals, mp 161-163°C (from MeOH); Rr 0.65 (MeOH: 
CH2Ch, 1 :9); IR: Vmax (DMSO)/cm-
1 3374 (N-H) and 1343 (S=O); OH (300 MHz, 
DMSO-d6) 1.75 (2H, m -NHCH2CH2CH2NHSOr ), 2.92 (2H, t, J 6.85 Hz -
CH2(CH2)2NHS02Ar), 3.2 (2H, m,-(CH2)2CH2NHS02Ar), 6.3 (H, d, J 5.4 Hz, H3 1), 
7.16 (H, t, J 6.0 Hz, -(CH2)~HS02), 7.37 (H, dd, J 6.6 and 8.8 Hz), 7.61-8.4 (lOH, m); 
oe (75MHz, CDCb) 27.8, 30.6, 38.1, 98.6, 117.4, 122.2, 123.9, 127.2, 127.4, 127.4, 
127.7, 128.5, 129.0, 129.3, 131.7, 133.3, 134.0, 137.5, 149.0, 149.9 and 151.7; Anal. 
Calc for HRMS C22H2oCIN302S; C, 61.0%; H, 4.7%; N, 9.9%; S, 7.5%; m/z 425.09648. 











4-Chloro-N- [3-(7' -chloro-quinolin-4' -ylamino )-propyI1-benzenesulfonamide (82) 
- (0.46 g, 95 %) as off white crystals, mp 174-177°C (from MeOH); Rf 0.36 (MeOH: 
CH2Ch, 1:9); IR: Vmax (DMSO)/cm-
l 3345 (N-H) and 1343 (S=O); OH (300 MHz, 
DMSO-d6) 1.75 (2H, quin, J 4 x 7 Hz, -NHCH2CH2CH2NHS02-), 2.88 (2H, t, J 6.0 Hz 
ArNHCHlCH2)2NHS02Ar), 3.22 (2H, m, ArNH(CH2)2CH2NHS02Ar), 6.37(H, d, J 5.4 
Hz, H3'), 7.18 (H, t, J 5.4 Hz -(CH2)JNHS02-),7.42(H, dd, J 2.2 and 9.1 Hz, H6'), 7.58-
7.77 (6H, m), 8.18 (H, d, J 9.1 Hz,H5'), 8.36 (H, d, J 5.4 Hz, H2'); Oe (75 MHz, DMSO-
d6) 27.7, 30.6, 30.7, 98.6, 117.4, 123.9, 124.0, 127.4, 128.3, 129.0, 129.2, 133.3, 133.4, 
137.2, 139.3, 148.9, 149.9 and 151.7; Anal. Calc for C18H17ChN30 2S; C, 52.7%; H, 
4.2%; N, 10.2%; S, 7.8%; mlz 409.04250. Found C, 53.1%; H, 4.4%; N, 9.9%; S, 7.7%; 
HRMS (EI) mlz 409.0422 (Mt 
7-Chloro-4-piperazin-1-yl-q uinoline (111). - 4,7 -Dichloroquinoline 
(2.0 g, 10.1 mmol) was treated with piperazine (5.22 g, 60.6 mmol) 
112 and stirred under nitrogen in the presence of N-methyl 2-
pyrrolidinone (7 cm3)l981, triethylamine (2.11 cm3, 15.15 mmol) and 
potassium carbonate (0.42 g, 3.03 mmol) at 135-145° C for 18 h. 
After cooling to room temperature, the product was washed with 
dichloromethane and brine, the organic layer separated, dried over anhydrous sodium 
sulphate, filtered and concentrated. Column chromatography (SiOl : 'NRtOH: MeOH, 
1.19) yielded the amine 111 (1.69 g, 85%) as orange/brown flakes; mp 109-113°C (from 
MeOH); Rf 0.29 ~OH: MeOH, 1:19); IR (Nujol): vmax/cm- l 3518 (NH2), 3437 
(NH2), 3029 (C=C), 1612 (NH2), 1582 (C=C and C=N); OH (300 MHz, CDC h) 3.15 
(8H, In, 4 x CH2), 6.81 (H, d, J 5.1 Hz, H3), 7.39 (lH, dd, J 1.5 and 6.6 Hz, H5), 7.93 
(lH, dd, J 4.8 and 6.6 Hz, H6), 8.02 (FI,.Q d, J 1.5 Hz, Hs) and 8.71 (H d, J 5.1 Hz, H2); oe 
(75 MHz, CDCh) 46.3 (2 x CH2), 53.7 (2 x CH2), 109.2, 122.2, 125.4, 126.3, 129.1, 
135.1, 150.4, 152.1 and 157.6; Anal Calc for C13H14CIN3; C, 63.0%; H, 5.7%; N, 













General procedure for preparation of piperazine 
sulfonamides 83-84 - 112 (4.04 nunol) and triethylamine (8.08 
mmol) were mixed in N, Nt dimethylformamide (1.7 
cm3fmmol)f951. Aryl sulfonyl chloride (5,66 mmol) was added 
and the mixture shaken for 18 h at 20°e. Water (5 cm3fnunol) 
was added resulting in the formation of a precipitate, which was 
isolated by filtration, Chromatography (Si02, MeOH: CH2Ch, 
1:4) yielded the desired sulfonamide. 
Aryl sulfonyl chlorides used: 4-Chlorosulfonyl chloride and 2-naphthalenesulfonyl 
chloride 
7-Chloro-4- [4-(naphthalene-2'-sulfonyl)-piperazin-l'-yl]-quinoline (83). - (0.88 g, 
88%) as off white crystals, mp 211-213°C (from MeOH); Rf 0.55 (MeOH: CH2Ch, 
1:9); IR: (DMSO)vmax fcm'l 3349 (N-H) and 1368 (S=O); bH (300 MHz, CDCh) 3.32 
(8H, dd, J 4.8 and 29,7,4 x CH2), 6,81 (H, d, J 5,1 Hz, H3), 7,29-8,02(9H, m,), 8A1(H, 
d, J 1.8 Hz), 8,7 (H, d, J 5.1 Hz, H2); be (75 MRz, CDCh) 46.3 (2 x CH2), 51.8(2 x 
CH2), 109,7, 121.9, 123.2, 124,8, 126,8, 128,0, 128.3, 129.25, 129.3, 129,5, 129,5, 
129,7, 132,5, l33,O, 135.3, l35,33, 150.3, 152,2 and 156.3; Anal. Cale for 
C23H2oClN302S; C, 63.1%; H, 4.6%; N, 9,6%; S, 7.3%; mlz 437,09647. Found C, 62.8% 
H, 4.6%; N, 9.3%; S, 7.2%; HRMS (El) mlz 437.0974 (Mt, 
7 -Chloro-4- [4-(4' -chloro-benzenesulfonyl)-piperidin-l-yl] quinoline (84). - (0. 76g, 
76%) as pale brown crystals, m.p. 159-162°C (from MeOH); Rf 0.69 (MeOH: CH2Ch, 
1:9); IR: Vmax (DMSO): fem'l 1347 (S=O); bH (300 MHz, CDCh) 3,39 (8H, d, J 5.7,4 x 
CH2), 6,83 (H, d, J 5,0 Hz, H3), 7.37 (H, dd, J2,2 and 9.1 Hz), 7.56-7.79 (6H, m), 8,03 
CH, d, J2.0 Hz), 8,73 (H, d, J 5.0 Hz, H2); be (75 MHz, CDCh) 46,0 (2 x CH2), 51.5 (2 
x CH2), 109,5, 121.7, 124,5, 126.6, 129.1, 129.2, 129,6, 129.8,l34.2, 135.2, 135.3, 
139.9,150.1, 151.9 and 156.0; Anal. Calc for C19H17C12N302S; C, 54,0%; H, 4.1%; N, 
10,0%; S, 7.6%; mlz 421.04185, Found C, 54.2%; H, 4,1%; N, 10,1%; S, 7.6%; HRMS 












HN~OH 2-(7'-Chloro-quinolin-4'-ylamino)-ethanol (114). - A 
mixture of 4,7-dichloroquinoline (5 g, 25.2 mmol) and 
ethanolamine (6.8 cm3, 113.4 mmol) was heated at 80°C 
for 1 h with stirring. Thereafter, at 135-145°C for 3h. 
Sodium hydroxide (1 M, 75 cm3) was added and the organic product extracted with ethyl 
acetate (6 x 250cm3). The combined organic extracts were washed with water (3 x 
50cm3), dried over anhydrous sodium sulfate and concentrated to yield the alcohol 114 
(1.78 g, 36%), mp 206-208°C (from MeOH); Rr 0.34 (MeOH: CH2Ch, 1:19); IR 
(Nujol): Ymax/cm-
1 3618 (OH), 3564 (N-H), 3029 (C=C), 1534 (C=C) and 1392 (OR); BH 
(300 MHz, CD30D) 3.5 (2H, t, J 5.7 Hz, ArNHCH2-), 3.84 (2H, t, J 5.7 Hz, 
ArNHCH2CH2-), 6.6 (H, d,JS.7 Hz, H3'), 7.4 (H, dd,J2.1 and 9 Hz, H6'), 7.8 (H, d,J 
2.1 Hz, H8'), 8.1 (H, d, J9.0, H5') and 8.35 (H, d, J 5.7 Hz, H2'); Be (75 NIHz, CD30D) 
30.1, 60.8, 118.8, 124.1, 124.4, 125,9, 127.5, 127.8, 136.36, 149.7 and 152.6; Anal. 
Calc for Cu HllCIN20; M 222.5; Found ~ (222,~) and (164, M+-NH(CH2)20H). 
Toluene-4-sulfonic acid 2-(7'-chloro-quinolin-
4'-ylamino) ethyl ester (112). - Triethylamine 
(33cm3, 23.97mmol) was added to a solution of 
114 (1. 78 g, 7.99 mmoli102] in CH2Ch (14 cm
3
). 
The solution was cooled to O°C in an ice-water bath. p - Toluenesulfonyl chloride (3.7 g, 
17.58 mmol) dissolved in CH2Clz (3 cm3) was slowly added to this cooled solution and 
stirred for 20 min at O°C. The reaction mixture is allowed to warm to 20°C and stirred 
for a further 40 min. The solution is transferred to a separating funnel and washed with 
hydrochloric acid (2M, 2 x 20 cm3) and saturated sodium carbonate. The organic phase 
is dried over sodium sulfate, filtered and concentrated under reduced pressure. The 
crude product was chromatographed (Si02, MeOH:CH2Clz, 1: 19) to give the tosylate 
112 (0.68g, 39%); mp 141-143°C (from EtOAc/pet ether; RrO.5 (MeOH-CH2Ch. 1:19); 
IR (Nujol): Yrnax/cm-1 3225 (N-H), 1557 (C=C), 1416 (S=O) and 1147 (S=O); BH (400 
MHz, acetone-d6) 2.26 (3H, s, CH3) 3.74 (2H, m, ArNHCH2-), 4.34 (2H, t, J 5.2 Hz, 
ArNHCH2CH2-), 6.45 (H, d, J 5.4 Hz, H3'), 6.70 (H br t, ArNH(CHz):PHSOzAr), 7.15 
(2H, dd, J 2.0 and 6.2 Hz,), 7.40 (H, dd, J 2.0 and 8.8 Hz, H6'), 7.65 (H, dd, J 2.0 and 











H2'); Oe (l00 MHz, acetone-d6) 22.1, 42.9, 69.1, 100. 5, 119.6, 124.5, 126.1, 129.2, 
129.8, 130.9, 131.3, 134.0, 134.4, 135. 6, 146.4, 151.0, 151.1, and 153.4; Anal. Calc for 
ClsH17CIN203S; C, 57.4%, H, 4.55%; N, 7.4%; mlz 376.06484; Found: C, 57.3%; H, 
4.4%; N, 7.2%; HRMS (EI) 376.06506 (Mt. 
CI 
~ .... 1 (7'-Chloro-quinolin-4'-yl)-(2-iodo-ethyl)-amine (113). -
HN' ..........",-
Iodine (0.55 g, 2.19 mmol) was added to a stirred solution of 
alcohol 114 (0.23 g, 0.73 mmol), imidazole (0.15 g, 2.19 
mmol) and triphenylphosphine (0.57 g, 2.19 mmol) dissolved 
in a mixture of ether: acetonitrile (3: 1) under nitrogen. The mixture was stirred at 20°C 
for 5 h. The resulting yellow suspension was filtered through celite and the filtrate 
concentrated. Column chromatography (Si02, MeOH: CH2Ch, 1: 19) afforded the 
product 113 (0.026 g, 11%) as a gum; Rr 0.32 (MeOH: CH2Ch, 1:19); IR (Nujol): 
vmaxicm-1 3563 (N-H), 3029 (C=C) and 1534 (C=C); OH (300 111Hz, CDCh) 3.37 (2H, 1, 
J 6.6 Hz, ArNHCH2CH2-) , 3.7 (2H, br t, ArNHCH2-), 6.38 (H, d, J 5.7 Hz, H3'), 7.36 
(H, dd, J 2.0 and 9.0 Hz, H6'), 7.83 (2H, m, H5' and H8') and 8.42 (H, d, J 5.7 Hz, H2'); 
Oe (75 MHz, CDCb) 8.4, 55.7, 104.5, 116.0, 121.2, 125.8, 128.8, 134.7, 149.4, 149.5 
and 151.4; Anal. Calc for CllHlQC1IN2; mlz 331.9577. Found HRMS (FAB) mlz 332.9 
(M+lt. 
CI 
R General procedure for preparation of 
HN/'...../NH-(CH2)n-*-R compounds 85-86 - 112 (0.322 mmol) was 
added to a solution of amine (0.644 mmol) 
in anhydrous acetonitrile (0.2 cm3/mmol) 
were mixed in a round-bottomed flask [103] 
and refluxed under nitrogen for 24 h. The crude mixture was chromatographed (Si02, 
MeOH: CH2C\z, 1: 19, then ~OH: MeOH, 1: 19) yielded the amine. 
Amines used: 3 -dimethylamino-l-propy lamine and piperazine 
N- [2-(7" -chloro-quinolin-4" -ylamino )-ethyl]-N', N' -dimethyl-propane-l, 3-
diamine (85). - (0.075 g, 66%); mp 61-67°C (from EtOAc/pet ether); Rr 0.25 CN1f40H-
MeOH, 1:19); IR (Nujol): vmax/cm-











1.66 (2H, quin, J7 Hz, ArNH (CH2)2NHCH2CHr), 2.17 (6H, s, 2 x CH3), 2.32 (2H, t, J 
7.2 Hz, ArNH (CH2)2NH(CH2)2CH2N(CH3)2), 2.70 (2H, t, J 6.8 Hz, 
ArNH(CH2)2NHCHr), 3.00 (2H, t, J 6.0 Hz, ArJ'ffiCH2CH2-), 3.31 (2H, m, 
ArNHCHr ), 5.92 (H, br s, ArNH), 6.37 (H, d, J 5.4 Hz, H3"), 7.32 (H, dd, J2.0 and 8.8 
Hz, H6"), 7.71 (H, d, J 8.8 Hz, H5"), 7.92 (H, d, J 2.0, H8") and 8.49 (H, d, J 5.4 Hz, 
H2"); Oe (100 .MHz, CDCh) 27.9, 41.9 (2 x CH3), 45.5,47.5,47.8, 58.0, 99.2, 117.2, 
121.3, 125.2, 128.7, 134.7, 149.0, 149.9 and 152.1; Anal. Calc for ClI#23CIN4; C, 
62.6%; H, 7.6%; N, 18.3%; mlz 306.16112. Found: C, 62.5%; H, 7.5%; N, 18.2%; 
HRMS (EI) 306.14589 (Mt. 
(7'-Chloro-quinolin-4'-yl)-(2-piperazine-l-yl-ethyl)-amine (86). -(0.1258 g, 37%); 
mp 124-127°C (from ETOAc/pet ether); Rf0.41 CNH40H: MeOH, 1:19); IR (Nujol): 
vrnax/cm·
1 2972 (N-H) and 1553 (C=C and C=N); OH (400 MHz, CDCh) 2.49 (4H, br t, 2 
x CH2), 2.74 (2H, t, J 6.4 Hz, ArNHCH2CH2-), 2.91(4H, t, 4.8 Hz, 2 x CH2), 3.29 (2H, 
q, J 3 x 6.0 Hz ArNHCH2CH2), 5.96 (H, br t, ArNH), 6.35 (H, d, J 5.6 Hz, H3'), 7.36 
(H, dd, J2.2 and 8.8 Hz, H6'), 7.66 (H, d, J 8.8 Hz, H5'), 7.94 (H, d, J 2.2 Hz, H8') and 
8.50 (H, d, J 5.6, H2'); Oe (100 MHz, CDCh) 38.8, 46.3 (2 x CH2), 54.0 (2 x CHz), 56.1, 
99.3, 117.2, 121.0, 125.3, 128.9, 134.8, 148.2, 149.6 and 152.1; Anal. Calc for 
C15H19CIN4; C, 61.9%; H, 6.6; N, 19.3%; mlz 290.12982; Found: C, 61.8%; H, 6.5%; N, 





propyl]-carbamic acid phenylester 
(90). -
A mixture of N, N' dimethylformamide 
(0.30 cm3, 3.82 mmol) and 
CI 
dichloromethane (15.3 cm3) was cooled 
to O°C and then added to phenyl chloroformate (0.48 cm3, 3.8 mmol) at O°c, This 
mixture was stirred at O°C for 30 min, then amine 107 (0.9 g, 3.8 mmo!) was added and 
the resulting heterogeneous mixture was stirred at O°C for 5 h. The solvent was removed 
under reduced pressure and column chromatography (Si02, MeOH: CH2Ch, 1: 19) 











EtOAC/pet ether); Rf 0.45 (MeOH: CH2Ch, 1 :9); IR (CHCh): Vmax!cm-1 3434 (CONH), 
3034 (C=C), 1714 (CO-O-C=C) and 1531 (C=C); OR (400 MHz, CDCh) l.94 (2H, m, 
Hz, ArNHCH2CH2-), 3.41-3,50 (4H, m, ArNH CH2-and ArNH CH2CH2CH2-), 5.59 (H, 
br t, NH), 6.21 (H, br t, NH), 6.39 (II, d, J 5.6 Hz, H31), 7.12 (H, dd, J 2 and 8.8 Hz, 
H6'), 7.20-7.39 (5H, m), 7.81 (H, d, J8.8 Hz, H5'), 7,93 (H, d, J2 Hz, H8') and 8.46 (H, 
d, J 5.6 Hz, H2'); Oc (100 MHz, CDCb) 28.6, 38.1, 39.5, 98.4, 98.5, 117.2, 121.5 (2 x 
H), 121.8, 125.5, 127.8, 129.4 (2 x H), 135,3, 148.4, 150.1, 150.9, 15l.0 and 155.8; 
Anal. Calc for C19H18CIN302; C, 64.1%; H, 5.1%; N, 1l.8%; mlz 355.1l. Found C, 





The amine 110 (0.09 g, 0.39 
mmol) was added to a stirred solution of carbamate 90 (0.1 g, 0.28 mmol) in anhydrous 
tetrahydrofuran (3.36 cm\ The resulting heterogeneous solution was stirred at 20°C for 
6h and subsequently at 50-60°C for 20 h. Column chromatography (Si02, ~OH: 
MeOH, 1 :9) afforded the urea 87 (0.87 g, 65%) as beige crystals; mp 166-168°C (from 
MeOH); RfO.6 ~OH: MeOH, 1:9); IR (MeOH): vmax!cm-1 3470 (N-H), 3423 (N-H), 
1643 (C=O) and 1559 (C=C); oH(400 MHz, DMSO-d6) l.85 (2H, quin, J 4 x 6.8 Hz, 
ArNH CH2CH2-), 3.30 (4H, m, 2 x CH2), 3.40 (2H, t, J 5.6 Hz, CH2), 3.51 (2H, t, J5.6 
Hz, CH2), 6.40 (II, d, J 5.6 Hz, H3'), 6.5(H, d, J 5.6 Hz, H3"),7.24 (H, dd, J2.4 and 9.0 
Hz, H6'), 7.34 (H, dd, J2.2 and 8.8 Hz, H6"), 7.69 (H, d, J2.4 Hz, H8'), 7.72 (H, d, J 
2.2 Hz, H8"), 7.95 (H, d, J9,0 Hz, H8'), 8.01 (H, d, J8.8 Hz, H8"), 8.24 (II, d, J5.6Hz, 
HZ'), 8.31 (H, d, J5.6 Hz, HZ"); oe(100 MHz, DMSO-d6) 29.4, 38.0, 38.8, 40.1,44.6, 
99.3, 118.1, 118.2, 122.9, 123.0, 124.4, 124.7, 124.7, 124.8, 128.2, 128.23, 134.1,149.7, 
149,8, 150.7, 150.8, 152.6, 152.6 and 159.8; Arla!. Calc for C2,J!24ChN60; C, 59.6%; 













m~~ HH ~I~ # .& ~ # CI N N I 
106 
1, 3 - Bis - [3 - (7' -
chloroquinolin -4'-ylamino)-
propyl]-urea (88). - To a 
stirred solution of carbamate 
90 (0.4 g, 1.13 mmol) in 
anhydrous tetrahydrofuran (14 cm\ amine 107 (0.37 g, 1.58 mmol) was added. The 
resulting solution is stirred at 50-60°C for 20 h. The precipitate that formed was 
removed by filtration and the mother liquor was concentrated. Column chromatography 
(Si02, 1\lH40H: MeOH, 1:9) afforded the urea 88 (0.41 g, 74%) as white crystals; 
mp126-129°C (from MeOH); Rr 0.34 ~OH: MeOH, 1:9); IR (MeOH): vrnax/cm-1 
3470(N-H), 3423 (N-H), 1643 (C=O) and 1559 (C=C); DR (400 MHz, DMSO-d6): 1.75 
(4H, quin, J 4 x 6.8 Hz, 2 x CH2), 3.12 (4H, q, J3 x 6.5 Hz, 2 x CH2), 3.26 (4H, q, J3 x 
6.4 Hz, 2 x CH2), 6.50 (2ll, d, J 5.6 Hz, H3'), 7.37 (2H, dd, J 2.0 and 8.8 Hz, H6'), 7.77 
(2H, d, J 2.0 Hz, H8'), 8.46 (2H, d, J, 9.2, H5'), 8.33 (2H, d, J 5.6, H2'); Dc (75 MHz, 
DMSO-d6) 29.5, 37.8, 54.81, 99.3, 117.3, 124.7, 124.8, 127.9, 134.2, 149.5, 150.9, 
152.3 and 159.3; AnaL Calc for C2.JI24ChN60; C, 60.4%; H, 5.3%; N, 16.9%; mlz 
496.15. Found C, 60.2%; H, 5.4%; N, 16.5%; MS (FAB) mlz 497.2 (M+lt, 
acid Q 0 (3-Dimethylamino-propyl-carbamic I b A ~ ~ /" phenylester (91). - A mixture of N, N' N' .........",.. ..... N 
H I dimethylformamide (1.51 cm3, 19.5 mmol) and 
dichloromethane (78 cm3) was cooled to 00 and then to phenyl chloroformate (2.4 cm3, 
19. 5mmol) at O°C.This mixture was stirred at O°C for 30 min then 3-Dimethylamino-l-
propyl amine (2.0 g, 19.5 mmol) was then added and the resulting solution was stirred at 
O°C for 7 h. The solvent was removed under reduced pressure and column 
chromatography (Si02, MeOH: CH2Ch, 1:9) yielded the carbamate 91 (1.7 g. 40%) as 
an off white a white gelatinous material; Rf 0.25 (MeOH: CH2Ch, 1 :9); IR (CHCh): 
vrnax/cm-1 34238 (N-H), 3056 (C=C), 1714.42 (CO-O-C=C) and 1511 (C=C); DR (300 
MHz, CDCb) 2.03 (2ll, m, -NHCH2CH2CH2N(CH3)2), 2.69 (6H, br d, 2 x CH3), 2.99 
(2H, m, -NHCH2CH2CH2N(CH3)2), 3.36 (2H, m, -NHCH2CH2CH2N(CH3)2), 5.93 (ll, 











38.21,42.9,43.3, 55.68, 115.5, 120.0, 121.6, 125.3, 129.2, 129.45 and 156.52; Calc for 
C12HlSNzOz; mlz 222.1368. Found HRMS (FAB) mlz 223.2 (M+lt. 
CI 
o I 1-[3-(7'-Chloro-quinolin-4'-
/'... /'... ~ /'... /N, ylamino )-propyl]-3-(2-
HN"" '-.../"'N N/ '-.../ , 
H H 
dimethylamino-propyl)-urea (89). 
- Method (a): To a stirred solution 
of carbamate 91(0.2 g, 0.90 mmol) 
in anhydrous tetrahydrofuran (11 cm3), amine 107 (0.17 g, 0.72 mmol) is added. The 
resulting solution was stirred at 50-60°C for 20 h. Column chromatography (SiOz, 
NH40H: MeOH, 1 :9) afforded the urea 89 (0.14 g, 54%) as a beige gum. 
Rf 0.1 (NH40H: MeOH, 1:9); IR (MeOH): vmax/cm-! 3467 (N-H), 3423 (N-H), 3028 
(C=C), 1616 (C=O) and 1559 (C=C); BH (400 MHz, DMSO-d6) 1.74 (4H, m, 2 x CH2), 
2.27 (6H, s, 2 xCI-h), 2.68 (4H, t, 16.4 Hz, 2 x Cl:h), 3.3 (4H, t, 16.8 Hz; CH2), 6.45 
(H, d, 15.4 Hz, H3'), 7.41 (H, dd, 12.0 and 9.0 Hz, H6'), 7.75 (H, d, 12.0 Hz, H8'), 8.21 
(H, d, 19.0 Hz, H5') and 8.37 (H, d, J 5.4 Hz, H2'), Be (l00 MHz, DMSO-d6) 31.8, 32.7, 
415.5 (2 x CH3), 42.9, 55.3,58.7,99.3, 118.2, 124.7, 124.7, 128.2, 134.0, 149.5, 149.8, 
150.9,152.6 and 159.2; Anal. Calc for CI8Hz6CINsO; mlz 363.1826. Found MS (FAB) 
mlz 364.3 (M+lt. 
Method (b): To a stirred solution of carbamate 91 (0.2 g, 0.90 mmol) in anhydrous N, N' 
dimethylformamide (11 cm31, amine 107 (0.17 g, 0.99 mmol) is added. The resulting 
solution is stirred at 50-60°C for 20 h. The suspension was then transferred to a 
separating funnel and washed with water (2 x 25 cm3) and extracted with ethyl acetate 
(3 x 50 cm\ The combined organic extracts were dried over anhydrous sodium sulfate 
and concentrated. Column chromatography (SiOz, CH2Cb: MeOH: Et3N, 8:2:0.1) 
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